?

Discussions and Knowledge Gaps

2

Does RNF213-mediated NF-κB activation and IL-6 amplification constitute a central inflammatory driver of moyamoya disease pathogenesis, and how does the MMD-associated RNF213 p.R4810K variant convert genetic susceptibility into the progressive steno-occlusive arteriopathy that defines the disease?

KNOWLEDGE GAP OPEN gap_moyamoya_rnf213_nfkb

Attached to

pathophysiology#Progressive steno-occlusive intracranial arteriopathy pathophysiology#RNF213-associated angiogenic and remodeling dysregulation pathophysiology#RNF213 loss-of-function Hippo-YAP/TAZ-VEGFR2 activation

RNF213, the major East Asian susceptibility gene for moyamoya disease, is an E3 ubiquitin ligase whose precise pathogenic mechanism is unresolved. Yasuda et al. (2026, PMID:41891799) identify RNF213 as a critical regulator of the IL-6 amplifier (IL6-Amp), an NF-κB/STAT3 inflammatory module active in non-immune cells: RNF213 knockdown selectively suppressed NF-κB target genes and reduced IL-6 expression, and RNF213 depletion attenuated inflammation in an NF-κB-dependent in vivo model. The disease-associated p.R4810K variant strengthens the RNF213-TRAF2 interaction, enhancing TNF-α-NF-κB signaling and IL6-Amp activation, with genotype-dependent NF-κB p65/STAT3 phosphorylation seen in patient superficial temporal arteries. This positions an inflammatory axis alongside the existing angiogenic and Hippo-YAP/TAZ-VEGFR2 mechanisms, but it remains unclear whether NF-κB/IL6-Amp activation is an initiating driver of vascular wall remodeling and stenosis or a parallel/amplifying process, and how it interacts with the angiogenic dysregulation already modeled. The upstream physiological triggers of IL6-Amp induction in cerebral vessels and whether anti-inflammatory or anti-IL-6 strategies can slow steno-occlusive progression in p.R4810K carriers are also unknown.

Proposed experiments

Genotype-stratified vascular inflammation and stenosis-progression study

genotype-stratified translational cohort with cell-based mechanistic assays

exp_moyamoya_rnf213_nfkb_vascular_progression

Combine longitudinal imaging of intracranial stenosis with molecular profiling of RNF213-genotyped MMD cohorts and matched vascular cells. Stratify patients by RNF213 p.R4810K status (homozygous, heterozygous, wild-type) and quantify IL6-Amp activation (NF-κB p65 and STAT3 phosphorylation, IL-6 output) in superficial temporal artery samples and in patient-derived arachnoid/endothelial cells stimulated with TNF-α plus IL-6, while tracking radiographic stenosis progression over time. Test whether RNF213-TRAF2-dependent NF-κB signaling predicts and mechanistically precedes vascular remodeling.

Readouts

Genotype-dependent IL6-Amp activation in vessel wall

pathophysiology#RNF213-associated angiogenic and remodeling dysregulation

Quantify phosphorylated NF-κB p65 and STAT3 and IL-6 expression in superficial temporal artery tissue and stimulated patient-derived vascular cells across RNF213 genotypes to test whether the p.R4810K variant amplifies NF-κB/IL6-Amp inflammatory signaling.

immunohistochemistry for phospho-NF-κB p65 and phospho-STAT3 IL-6 expression quantification in stimulated vascular cells

Direction: POSITIVE

NF-κB-dependence of inflammatory output

pathophysiology#RNF213 loss-of-function Hippo-YAP/TAZ-VEGFR2 activation

Use RNF213 knockdown and TRAF2/NF-κB perturbation in vascular cell models to determine whether RNF213-driven IL-6 amplification is mediated through the TRAF2-NF-κB axis rather than the Hippo-YAP/TAZ-VEGFR2 program.

RNF213 knockdown with NF-κB target-gene readout

Direction: POSITIVE

Inflammatory signature versus stenosis progression

pathophysiology#Progressive steno-occlusive intracranial arteriopathy

Correlate baseline IL6-Amp/NF-κB activation markers with subsequent radiographic progression of intracranial stenosis to test whether inflammatory activation precedes and predicts steno-occlusive remodeling.

serial neurovascular imaging of intracranial stenosis

Direction: POSITIVE

Decision criterion

An RNF213-NF-κB/IL6-Amp inflammatory driver is supported if (1) p.R4810K genotype dose-dependently increases NF-κB p65/STAT3 phosphorylation and IL-6 output in vessel wall and patient-derived cells, (2) RNF213 knockdown suppresses inflammatory output in a TRAF2-NF-κB-dependent manner, and (3) baseline inflammatory activation predicts subsequent stenosis progression; a primarily parallel/amplifying role is favored if inflammatory markers do not precede or predict remodeling.

Would support

pathophysiology#RNF213-associated angiogenic and remodeling dysregulation pathophysiology#Progressive steno-occlusive intracranial arteriopathy

Show evidence (2 references)

PMID:41891799 SUPPORT In Vitro

"Here, we identify RNF213 as a critical regulator of the IL-6 amplifier (IL6-Amp), a mechanism that enhances NF-κB-mediated inflammation in the presence of IL-6-STAT3 in non-immune cells."

This cell-based study identifies RNF213 as a regulator of the NF-κB-driven IL-6 amplifier, motivating the gap about whether this inflammatory axis is a central MMD mechanism.

PMID:41891799 SUPPORT In Vitro

"The MMD-associated RNF213 p.R4810K variant enhanced NF-κB activation by strengthening the interaction between RNF213 and TRAF2, a key adaptor in TNF-α-NF-κB signaling."

This biochemical/cell-based finding links the disease-associated p.R4810K variant to enhanced TRAF2-NF-κB signaling, supporting the gap question of how RNF213 genetic variation drives the inflammatory cascade.

What are the precise upstream triggers that induce RNF213-TRAF2-mediated NF-κB activation and IL-6 amplification in cerebral vessels, and what are the downstream consequences of this inflammatory cascade for the characteristic progressive intracranial arterial stenosis and moyamoya collateral vessel formation that define moyamoya disease?

KNOWLEDGE GAP OPEN gap_moyamoya_rnf213_traf2_triggers_outcomes

Attached to

pathophysiology#RNF213-TRAF2-mediated NF-κB-IL-6 amplification pathophysiology#Progressive steno-occlusive intracranial arteriopathy

Inflammatory and autoimmune responses are implicated in moyamoya disease (MMD), but the precise molecular mechanisms remain poorly understood. RNF213 is the key MMD susceptibility gene and has been linked to inflammatory signaling, yet its role in NF-κB-driven inflammation was unclear. Yasuda et al. (PMID:41891799) establish that RNF213 acts as a critical regulator of the IL-6 amplifier (IL6-Amp) and directly interacts with TRAF2 to enhance inflammatory NF-κB signaling, with the p.R4810K variant strengthening the RNF213-TRAF2 interaction. What remains unresolved is the upstream side of this axis — which physiological or environmental stimuli (e.g., infection-associated cytokine exposure, TNF-α, IL-6) initiate IL6-Amp induction in cerebral vessel walls — and the downstream side: whether and how sustained NF-κB/IL-6 amplification mechanistically produces the medial and intimal remodeling, smooth-muscle and endothelial changes, and fragile collateral angiogenesis that manifest as progressive steno-occlusive arteriopathy. It is also unclear how RNF213 genetic variation, particularly the dose of p.R4810K, quantitatively tunes the inflammatory cascade and couples genotype to the rate and pattern of stenosis and collateral development. Resolving these upstream triggers and downstream effectors is needed to determine whether anti-inflammatory or anti-IL-6 intervention could modify disease progression.

Seeded from PMID:41891799 — RNF213-TRAF2 interaction enhances inflammatory responses via NF-kB activation in moyamoya disease. Complements the broader same-source discussion gap_moyamoya_rnf213_nfkb, narrowing it to the unresolved upstream triggers and downstream steno-occlusive/collateral outcomes.

⚙

Pathophysiology

4

Progressive steno-occlusive intracranial arteriopathy

Progressive stenosis of the terminal internal carotid arteries and circle of Willis lowers cerebral perfusion and drives formation of fragile collateral vessels, which underlies ischemic and hemorrhagic presentations.

endothelial cell CL:0000115

vasculature development GO:0001944 ⚠ ABNORMAL

Show evidence (1 reference)

DOI:10.3171/2024.1.JNS221977 SUPPORT Human Clinical

"Moyamoya disease (MMD) is characterized by idiopathic, progressive stenosis of the circle of Willis and the terminal portion of the internal carotid arteries with the development of prominent small collateral vessels and a characteristic moyamoya or puff-of-smoke radiographic appearance."

This review directly states the defining vascular pathology and collateralization.

RNF213-associated angiogenic and remodeling dysregulation

RNF213 variants, especially p.R4810K in East Asian populations, contribute to susceptibility and may perturb endothelial angiogenesis, vascular remodeling, and cerebral blood flow regulation.

endothelial cell CL:0000115

angiogenesis GO:0001525 ⚠ ABNORMAL vascular endothelial growth factor receptor signaling pathway GO:0048010 ⚠ ABNORMAL

Downstream

Progressive steno-occlusive intracranial arteriopathy Dysregulated endothelial angiogenesis and vascular remodeling driven by RNF213 variants contributes to progressive intracranial arterial stenosis and collateral formation.

Show evidence (1 reference)

DOI:10.3390/biomedicines13010017 SUPPORT Human Clinical

"This gene encodes an E3 ubiquitin ligase with diverse roles in angiogenesis, vascular remodeling, lipid metabolism, and cerebral blood flow regulation, yet its exact mechanisms in cerebrovascular pathology remain incompletely understood."

This supports RNF213's proposed involvement in vascular remodeling and angiogenesis while preserving mechanistic uncertainty.

RNF213 loss-of-function Hippo-YAP/TAZ-VEGFR2 activation

Experimental RNF213 loss activates YAP/TAZ and VEGFR2-linked endothelial angiogenic programs, providing a more specific signaling mechanism for pathological angiogenesis in moyamoya disease.

endothelial cell CL:0000115

vascular endothelial growth factor receptor signaling pathway GO:0048010 ↑ INCREASED

Downstream

RNF213-associated angiogenic and remodeling dysregulation YAP/TAZ-driven VEGFR2 overexpression feeds into broader dysregulation of endothelial angiogenesis and vascular remodeling.

Show evidence (1 reference)

DOI:10.1093/brain/awad225 SUPPORT In Vitro

"Endothelial knockdown of RNF213 activated the Hippo pathway effector Yes-associated protein (YAP)/tafazzin (TAZ) and promoted the overexpression of the downstream effector VEGFR2."

This cell-based component of the study supports Hippo-YAP/TAZ-VEGFR2 activation after RNF213 knockdown.

RNF213-TRAF2-mediated NF-κB-IL-6 amplification

RNF213, particularly the p.R4810K variant, directly interacts with TRAF2 to enhance TNF-α-driven NF-κB activation and amplify IL-6 production via the IL-6 amplifier (IL6-Amp) mechanism. This NF-κB-IL-6-STAT3 axis drives inflammatory responses in vascular tissues and contributes to MMD pathogenesis.

endothelial cell CL:0000115

cytokine production GO:0001816 ↑ INCREASED inflammatory response GO:0006954 ↑ INCREASED

Downstream

Progressive steno-occlusive intracranial arteriopathy Chronic NF-κB-driven IL-6 amplification and inflammatory signaling in vascular tissue drives endothelial dysfunction, vascular remodeling dysregulation, and progressive stenosis.

Show evidence (3 references)

PMID:41891799 SUPPORT In Vitro

"RNF213 as a critical regulator of the IL-6 amplifier (IL6-Amp), a mechanism that enhances NF-κB-mediated inflammation in the presence of IL-6-STAT3 in non-immune cells."

This identifies RNF213's role in regulating the IL-6 amplifier mechanism that enhances NF-κB inflammation.

PMID:41891799 SUPPORT In Vitro

"The MMD-associated RNF213 p.R4810K variant enhanced NF-κB activation by strengthening the interaction between RNF213 and TRAF2, a key adaptor in TNF-α-NF-κB signaling."

This demonstrates that the pathogenic p.R4810K variant amplifies NF-κB signaling through enhanced RNF213-TRAF2 interaction.

PMID:41891799 SUPPORT Human Clinical

"histopathological analysis of superficial temporal arteries from MMD patients revealed genotype-dependent IL6-Amp activation, with pronounced phosphorylation of NF-κB p65 and STAT3 in homozygous carriers."

Vessel histopathology directly confirms IL6-Amp activation and NF-κB pathway engagement in MMD patient arterial tissue.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Cardiovascular 2

Intracranial arterial stenosis Arterial stenosis HP:0100545

Show evidence (1 reference)

DOI:10.3171/2024.1.JNS221977 SUPPORT Human Clinical

"Moyamoya disease (MMD) is characterized by idiopathic, progressive stenosis of the circle of Willis and the terminal portion of the internal carotid arteries with the development of prominent small collateral vessels and a characteristic moyamoya or puff-of-smoke radiographic appearance."

This defines the core steno-occlusive phenotype.

Ischemic symptoms and stroke Ischemic stroke HP:0002140

Show evidence (1 reference)

DOI:10.3171/2024.1.JNS221977 SUPPORT Human Clinical

"Ischemic symptoms are the most common presentation in pediatric and adult populations, but adult patients are nearly twice as likely to present with intracranial hemorrhage compared to their pediatric counterparts."

This supports ischemic presentations and age-related hemorrhagic differences.

Nervous System 3

Post-revascularization seizure Seizure HP:0001250

Show evidence (1 reference)

PMID:37995995 SUPPORT Human Clinical

"Ten patients developed seizures after revascularization for MMD."

This cohort supports seizures specifically after revascularization in patients with MMD.

Cognitive impairment Cognitive impairment HP:0100543

Show evidence (1 reference)

PMID:36996746 SUPPORT Human Clinical

"Cognitive impairment was common."

This adult longitudinal cohort directly supports cognitive impairment in MMD.

Hemiparesis Hemiparesis HP:0001269

Show evidence (1 reference)

PMID:31439486 SUPPORT Human Clinical

"A 23-year-old woman presented with a headache and transient hemiparesis on her left side."

This case report directly supports transient hemiparesis in an MMD presentation.

Other 2

Transient ischemic attack Transient ischemic attack HP:0002326

Show evidence (1 reference)

DOI:10.1159/000540254 SUPPORT Human Clinical

"In the Japan Adult Moyamoya trial, a randomized controlled trial for bilateral extracranial-intracranial direct bypass versus conservative therapy in patients with MMD, who had intracranial hemorrhage, recurrent bleeding, completed stroke or crescendo transient ischemic attack was significantly..."

This review of the adult randomized trial includes crescendo TIA among clinical outcomes in MMD.

Intracranial hemorrhage Intracranial hemorrhage HP:0002170

Show evidence (1 reference)

DOI:10.3171/2024.1.JNS221977 SUPPORT Human Clinical

"Ischemic symptoms are the most common presentation in pediatric and adult populations, but adult patients are nearly twice as likely to present with intracranial hemorrhage compared to their pediatric counterparts."

This supports intracranial hemorrhage as an adult-enriched presentation.

🧬

Genetic Associations

3

RNF213 susceptibility (Predisposing)

Gene: RNF213 hgnc:14539

Show evidence (1 reference)

DOI:10.3390/biomedicines13010017 SUPPORT Human Clinical

"Initially identified as the primary susceptibility gene for MMD, RNF213—notably the p.R4810K variant—has been strongly linked to intracranial artery stenosis (ICAS) and various ischemic stroke subtypes, particularly in East Asian populations."

This supports RNF213 p.R4810K as a susceptibility variant rather than a fully penetrant cause.

RNF213 variant and infectious burden interaction (Predisposing)

Gene: RNF213 hgnc:14539

Show evidence (1 reference)

DOI:10.1161/JAHA.124.036830 SUPPORT Human Clinical

"The RNF213 variant and increased IB were associated with intracranial artery stenosis in MMD."

This supports a gene-environment association with stenosis severity.

GUCY1A3-associated vascular signaling susceptibility (Predisposing)

Gene: GUCY1A3 hgnc:4685

Show evidence (1 reference)

PMID:34381413 SUPPORT Human Clinical

"Genetic studies identified RNF213/Mysterin and GUCY1A3 as disease-causing genes."

This review supports GUCY1A3/GUCY1A1 as a moyamoya-associated vascular signaling gene.

💊

Medical Actions

2

Surgical revascularization

Action: surgical procedure MAXO:0000004

Surgical revascularization is the main treatment for symptomatic disease; direct, indirect, or combined bypass approaches are selected based on age, symptoms, anatomy, and center expertise.

Show evidence (2 references)

DOI:10.3171/2024.1.JNS221977 SUPPORT Human Clinical

"Surgical revascularization is indicated in symptomatic cases, and antiplatelet therapy may be a useful adjunct to prevent recurrent symptoms."

This review directly supports revascularization for symptomatic MMD.

DOI:10.1159/000540254 SUPPORT Human Clinical

"In the Japan Adult Moyamoya trial, a randomized controlled trial for bilateral extracranial-intracranial direct bypass versus conservative therapy in patients with MMD, who had intracranial hemorrhage, recurrent bleeding, completed stroke or crescendo transient ischemic attack was significantly..."

This supports direct bypass benefit over conservative care for hemorrhagic or high-risk adult MMD presentations.

Antiplatelet therapy

Action: Pharmacotherapy NCIT:C15986

Antiplatelet therapy can be considered as an adjunct in selected patients, particularly to reduce recurrent ischemic symptoms.

Show evidence (1 reference)

DOI:10.1159/000540254 PARTIAL Human Clinical

"The latest Japanese Guidelines and American Scientific Statement described that antiplatelet therapy can be considered reasonable."

This supports guideline-consistent adjunctive use but not definitive disease modification.

{ }

Source YAML

click to show

name: Moyamoya Disease
creation_date: "2026-05-04T22:23:50Z"
updated_date: "2026-05-05T00:56:18Z"
description: >-
  Moyamoya disease is an idiopathic, progressive cerebrovascular arteriopathy
  characterized by stenosis or occlusion of the circle of Willis and terminal
  internal carotid arteries with development of prominent basal collateral
  vessels that create the radiographic "puff-of-smoke" appearance.
category: Complex
disease_term:
  preferred_term: Moyamoya disease
  term:
    id: MONDO:0016820
    label: Moyamoya disease
parents:
- Vascular disorder
synonyms:
- MMD
- Moyamoya angiopathy
pathophysiology:
- name: Progressive steno-occlusive intracranial arteriopathy
  description: >-
    Progressive stenosis of the terminal internal carotid arteries and circle
    of Willis lowers cerebral perfusion and drives formation of fragile
    collateral vessels, which underlies ischemic and hemorrhagic presentations.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: vasculature development
    modifier: ABNORMAL
    term:
      id: GO:0001944
      label: vasculature development
  evidence:
  - reference: DOI:10.3171/2024.1.JNS221977
    reference_title: "Management of moyamoya disease: a review of current and future therapeutic strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Moyamoya disease (MMD) is characterized by idiopathic, progressive stenosis of the circle of Willis and the terminal portion of the internal carotid arteries with the development of prominent small collateral vessels and a characteristic moyamoya or puff-of-smoke radiographic appearance.
    explanation: This review directly states the defining vascular pathology and collateralization.
- name: RNF213-associated angiogenic and remodeling dysregulation
  description: >-
    RNF213 variants, especially p.R4810K in East Asian populations, contribute
    to susceptibility and may perturb endothelial angiogenesis, vascular
    remodeling, and cerebral blood flow regulation.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: angiogenesis
    modifier: ABNORMAL
    term:
      id: GO:0001525
      label: angiogenesis
  - preferred_term: vascular endothelial growth factor receptor signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0048010
      label: vascular endothelial growth factor receptor signaling pathway
  evidence:
  - reference: DOI:10.3390/biomedicines13010017
    reference_title: "Exploring RNF213 in Ischemic Stroke and Moyamoya Disease: From Cellular Models to Clinical Insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This gene encodes an E3 ubiquitin ligase with diverse roles in angiogenesis, vascular remodeling, lipid metabolism, and cerebral blood flow regulation, yet its exact mechanisms in cerebrovascular pathology remain incompletely understood.
    explanation: This supports RNF213's proposed involvement in vascular remodeling and angiogenesis while preserving mechanistic uncertainty.
  downstream:
  - target: Progressive steno-occlusive intracranial arteriopathy
    description: Dysregulated endothelial angiogenesis and vascular remodeling driven by RNF213 variants contributes to progressive intracranial arterial stenosis and collateral formation.
- name: RNF213 loss-of-function Hippo-YAP/TAZ-VEGFR2 activation
  description: >-
    Experimental RNF213 loss activates YAP/TAZ and VEGFR2-linked endothelial
    angiogenic programs, providing a more specific signaling mechanism for
    pathological angiogenesis in moyamoya disease.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: vascular endothelial growth factor receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0048010
      label: vascular endothelial growth factor receptor signaling pathway
  evidence:
  - reference: DOI:10.1093/brain/awad225
    reference_title: "<i>RNF213</i> loss-of-function promotes pathological angiogenesis in moyamoya disease via the Hippo pathway"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Endothelial knockdown of RNF213 activated the Hippo pathway effector Yes-associated protein (YAP)/tafazzin (TAZ) and promoted the overexpression of the downstream effector VEGFR2.
    explanation: This cell-based component of the study supports Hippo-YAP/TAZ-VEGFR2 activation after RNF213 knockdown.
  downstream:
  - target: RNF213-associated angiogenic and remodeling dysregulation
    description: YAP/TAZ-driven VEGFR2 overexpression feeds into broader dysregulation of endothelial angiogenesis and vascular remodeling.
- name: RNF213-TRAF2-mediated NF-κB-IL-6 amplification
  description: >-
    RNF213, particularly the p.R4810K variant, directly interacts with TRAF2 to
    enhance TNF-α-driven NF-κB activation and amplify IL-6 production via the
    IL-6 amplifier (IL6-Amp) mechanism. This NF-κB-IL-6-STAT3 axis drives
    inflammatory responses in vascular tissues and contributes to MMD
    pathogenesis.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: cytokine production
    modifier: INCREASED
    term:
      id: GO:0001816
      label: cytokine production
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:41891799
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      RNF213 as a critical regulator of the IL-6 amplifier (IL6-Amp), a mechanism that
      enhances NF-κB-mediated inflammation in the presence of IL-6-STAT3 in non-immune cells.
    explanation: This identifies RNF213's role in regulating the IL-6 amplifier mechanism that enhances NF-κB inflammation.
  - reference: PMID:41891799
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The MMD-associated RNF213 p.R4810K variant enhanced NF-κB activation by
      strengthening the interaction between RNF213 and TRAF2, a key adaptor in
      TNF-α-NF-κB signaling.
    explanation: This demonstrates that the pathogenic p.R4810K variant amplifies NF-κB signaling through enhanced RNF213-TRAF2 interaction.
  - reference: PMID:41891799
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      histopathological analysis of superficial temporal arteries from MMD patients revealed
      genotype-dependent IL6-Amp activation, with pronounced phosphorylation of NF-κB
      p65 and STAT3 in homozygous carriers.
    explanation: Vessel histopathology directly confirms IL6-Amp activation and NF-κB pathway engagement in MMD patient arterial tissue.
  downstream:
  - target: Progressive steno-occlusive intracranial arteriopathy
    description: Chronic NF-κB-driven IL-6 amplification and inflammatory signaling in vascular tissue drives endothelial dysfunction, vascular remodeling dysregulation, and progressive stenosis.
phenotypes:
- category: Neurological
  name: Intracranial arterial stenosis
  diagnostic: true
  description: Progressive stenosis of intracranial arteries is the central diagnostic vascular abnormality.
  phenotype_term:
    preferred_term: Arterial stenosis
    term:
      id: HP:0100545
      label: Arterial stenosis
  evidence:
  - reference: DOI:10.3171/2024.1.JNS221977
    reference_title: "Management of moyamoya disease: a review of current and future therapeutic strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Moyamoya disease (MMD) is characterized by idiopathic, progressive stenosis of the circle of Willis and the terminal portion of the internal carotid arteries with the development of prominent small collateral vessels and a characteristic moyamoya or puff-of-smoke radiographic appearance.
    explanation: This defines the core steno-occlusive phenotype.
- category: Neurological
  name: Ischemic symptoms and stroke
  description: Ischemic symptoms are common across pediatric and adult populations.
  phenotype_term:
    preferred_term: Ischemic stroke
    term:
      id: HP:0002140
      label: Ischemic stroke
  evidence:
  - reference: DOI:10.3171/2024.1.JNS221977
    reference_title: "Management of moyamoya disease: a review of current and future therapeutic strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ischemic symptoms are the most common presentation in pediatric and adult populations, but adult patients are nearly twice as likely to present with intracranial hemorrhage compared to their pediatric counterparts.
    explanation: This supports ischemic presentations and age-related hemorrhagic differences.
- category: Neurological
  name: Transient ischemic attack
  description: Transient ischemic attacks are part of the ischemic presentation spectrum in MMD.
  phenotype_term:
    preferred_term: Transient ischemic attack
    term:
      id: HP:0002326
      label: Transient ischemic attack
  evidence:
  - reference: DOI:10.1159/000540254
    reference_title: "Adult Moyamoya disease and moyamoya syndrome: what’s new?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the Japan Adult Moyamoya trial, a randomized controlled trial for bilateral extracranial-intracranial direct bypass versus conservative therapy in patients with MMD, who had intracranial hemorrhage, recurrent bleeding, completed stroke or crescendo transient ischemic attack was significantly fewer with direct bypass than with conservative care.
    explanation: This review of the adult randomized trial includes crescendo TIA among clinical outcomes in MMD.
- category: Neurological
  name: Post-revascularization seizure
  description: Seizures have been reported after surgical revascularization in patients with MMD.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  review_notes: >-
    Scoped to post-revascularization seizures because the supporting cohort
    reports postoperative events. Reviewer-suggested HP:0025373 resolves locally
    to interictal EEG abnormality, so the broader seizure term is retained.
  evidence:
  - reference: PMID:37995995
    reference_title: Predictive Factors for Seizures after Revascularization in Patients with Moyamoya Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ten patients developed seizures after revascularization for MMD.
    explanation: This cohort supports seizures specifically after revascularization in patients with MMD.
- category: Neurological
  name: Cognitive impairment
  description: Adult MMD cohorts show frequent domain-specific cognitive impairment.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:36996746
    reference_title: Long-term study of the cognitive profile of Moyamoya Disease in adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cognitive impairment was common.
    explanation: This adult longitudinal cohort directly supports cognitive impairment in MMD.
- category: Neurological
  name: Hemiparesis
  description: Transient hemiparesis can occur in MMD as part of an ischemic or seizure-like presentation.
  phenotype_term:
    preferred_term: Hemiparesis
    term:
      id: HP:0001269
      label: Hemiparesis
  evidence:
  - reference: PMID:31439486
    reference_title: "Moyamoya disease with epileptic nystagmus: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 23-year-old woman presented with a headache and transient hemiparesis on her left side.
    explanation: This case report directly supports transient hemiparesis in an MMD presentation.
- category: Neurological
  name: Intracranial hemorrhage
  description: Adult patients may present with intracranial hemorrhage from fragile collateral vessels.
  phenotype_term:
    preferred_term: Intracranial hemorrhage
    term:
      id: HP:0002170
      label: Intracranial hemorrhage
  evidence:
  - reference: DOI:10.3171/2024.1.JNS221977
    reference_title: "Management of moyamoya disease: a review of current and future therapeutic strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ischemic symptoms are the most common presentation in pediatric and adult populations, but adult patients are nearly twice as likely to present with intracranial hemorrhage compared to their pediatric counterparts.
    explanation: This supports intracranial hemorrhage as an adult-enriched presentation.
genetic:
- name: RNF213 susceptibility
  association: Predisposing
  presence: Positive
  gene_term:
    preferred_term: RNF213
    term:
      id: hgnc:14539
      label: RNF213
  notes: >-
    RNF213, particularly p.R4810K, is a major susceptibility locus in East Asian
    moyamoya disease but is not deterministically causative in all patients.
  evidence:
  - reference: DOI:10.3390/biomedicines13010017
    reference_title: "Exploring RNF213 in Ischemic Stroke and Moyamoya Disease: From Cellular Models to Clinical Insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Initially identified as the primary susceptibility gene for MMD, RNF213—notably the p.R4810K variant—has been strongly linked to intracranial artery stenosis (ICAS) and various ischemic stroke subtypes, particularly in East Asian populations.
    explanation: This supports RNF213 p.R4810K as a susceptibility variant rather than a fully penetrant cause.
- name: RNF213 variant and infectious burden interaction
  association: Predisposing
  presence: Positive
  gene_term:
    preferred_term: RNF213
    term:
      id: hgnc:14539
      label: RNF213
  notes: >-
    Prospective evidence supports combined genetic and infectious-burden
    associations with severe intracranial arterial stenosis in MMD.
  evidence:
  - reference: DOI:10.1161/JAHA.124.036830
    reference_title: "RNF213 Variant and Infectious Burden Associated With Intracranial Artery Stenosis in Moyamoya Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The RNF213 variant and increased IB were associated with intracranial artery stenosis in MMD.
    explanation: This supports a gene-environment association with stenosis severity.
- name: GUCY1A3-associated vascular signaling susceptibility
  association: Predisposing
  presence: Positive
  gene_term:
    preferred_term: GUCY1A3
    term:
      id: hgnc:4685
      label: GUCY1A1
  notes: >-
    GUCY1A3 is an older synonym for the HGNC-approved symbol GUCY1A1, encoding
    the soluble guanylate cyclase alpha subunit in the NO-sGC-cGMP pathway.
  evidence:
  - reference: PMID:34381413
    reference_title: "RNF213 and GUCY1A3 in Moyamoya Disease: Key Regulators of Metabolism, Inflammation, and Vascular Stability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic studies identified RNF213/Mysterin and GUCY1A3 as disease-causing genes.
    explanation: This review supports GUCY1A3/GUCY1A1 as a moyamoya-associated vascular signaling gene.
diagnosis:
- name: Neurovascular imaging
  description: >-
    Diagnosis is based on vascular imaging showing terminal internal carotid or
    circle-of-Willis stenosis with moyamoya collateral vessels; advanced MRI may
    help distinguish adult MMD from atherosclerosis.
  diagnosis_term:
    preferred_term: diagnostic imaging
    term:
      id: MAXO:0000005
      label: clinical imaging procedure
  results: Imaging demonstrates intracranial stenosis or occlusion and moyamoya collateral networks.
  evidence:
  - reference: DOI:10.1159/000540254
    reference_title: "Adult Moyamoya disease and moyamoya syndrome: what’s new?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3-dimensional constructive interference in steady-state MRI is useful for the differential diagnosis of MMD from atherosclerosis.
    explanation: This supports MRI-based diagnostic differentiation in adult moyamoya.
- name: Updated unilateral moyamoya diagnostic criteria
  description: >-
    Updated Japanese diagnostic criteria no longer require bilateral
    intracranial carotid involvement, reflecting evidence that unilateral MMD
    can progress.
  diagnosis_term:
    preferred_term: diagnostic imaging
    term:
      id: MAXO:0000005
      label: clinical imaging procedure
  results: Unilateral terminal internal carotid involvement with moyamoya vessels can meet updated diagnostic criteria.
  evidence:
  - reference: DOI:10.1159/000540254
    reference_title: "Adult Moyamoya disease and moyamoya syndrome: what’s new?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The latest guidelines by the Research Committee on MMD of the Japanese Ministry of Health, Labor, and Welfare, removed limitations of the previous definition that required bilateral involvement of the intracranial carotid artery to make the diagnosis, given the increasing evidence of progression to bilateral involvement in unilateral MMD.
    explanation: This supports unilateral MMD recognition in updated diagnostic criteria.
treatments:
- name: Surgical revascularization
  description: >-
    Surgical revascularization is the main treatment for symptomatic disease;
    direct, indirect, or combined bypass approaches are selected based on age,
    symptoms, anatomy, and center expertise.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: DOI:10.3171/2024.1.JNS221977
    reference_title: "Management of moyamoya disease: a review of current and future therapeutic strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surgical revascularization is indicated in symptomatic cases, and antiplatelet therapy may be a useful adjunct to prevent recurrent symptoms.
    explanation: This review directly supports revascularization for symptomatic MMD.
  - reference: DOI:10.1159/000540254
    reference_title: "Adult Moyamoya disease and moyamoya syndrome: what’s new?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the Japan Adult Moyamoya trial, a randomized controlled trial for bilateral extracranial-intracranial direct bypass versus conservative therapy in patients with MMD, who had intracranial hemorrhage, recurrent bleeding, completed stroke or crescendo transient ischemic attack was significantly fewer with direct bypass than with conservative care.
    explanation: This supports direct bypass benefit over conservative care for hemorrhagic or high-risk adult MMD presentations.
- name: Antiplatelet therapy
  description: >-
    Antiplatelet therapy can be considered as an adjunct in selected patients,
    particularly to reduce recurrent ischemic symptoms.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: DOI:10.1159/000540254
    reference_title: "Adult Moyamoya disease and moyamoya syndrome: what’s new?"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The latest Japanese Guidelines and American Scientific Statement described that antiplatelet therapy can be considered reasonable.
    explanation: This supports guideline-consistent adjunctive use but not definitive disease modification.
discussions:
- discussion_id: gap_moyamoya_rnf213_nfkb
  prompt: >-
    Does RNF213-mediated NF-κB activation and IL-6 amplification constitute a
    central inflammatory driver of moyamoya disease pathogenesis, and how does the
    MMD-associated RNF213 p.R4810K variant convert genetic susceptibility into the
    progressive steno-occlusive arteriopathy that defines the disease?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Progressive steno-occlusive intracranial arteriopathy
  - pathophysiology#RNF213-associated angiogenic and remodeling dysregulation
  - pathophysiology#RNF213 loss-of-function Hippo-YAP/TAZ-VEGFR2 activation
  rationale: >-
    RNF213, the major East Asian susceptibility gene for moyamoya disease, is an
    E3 ubiquitin ligase whose precise pathogenic mechanism is unresolved.
    Yasuda et al. (2026, PMID:41891799) identify RNF213 as a critical regulator
    of the IL-6 amplifier (IL6-Amp), an NF-κB/STAT3 inflammatory module active in
    non-immune cells: RNF213 knockdown selectively suppressed NF-κB target genes
    and reduced IL-6 expression, and RNF213 depletion attenuated inflammation in
    an NF-κB-dependent in vivo model. The disease-associated p.R4810K variant
    strengthens the RNF213-TRAF2 interaction, enhancing TNF-α-NF-κB signaling and
    IL6-Amp activation, with genotype-dependent NF-κB p65/STAT3 phosphorylation
    seen in patient superficial temporal arteries. This positions an inflammatory
    axis alongside the existing angiogenic and Hippo-YAP/TAZ-VEGFR2 mechanisms,
    but it remains unclear whether NF-κB/IL6-Amp activation is an initiating
    driver of vascular wall remodeling and stenosis or a parallel/amplifying
    process, and how it interacts with the angiogenic dysregulation already
    modeled. The upstream physiological triggers of IL6-Amp induction in
    cerebral vessels and whether anti-inflammatory or anti-IL-6 strategies can
    slow steno-occlusive progression in p.R4810K carriers are also unknown.
  proposed_experiments:
  - experiment_id: exp_moyamoya_rnf213_nfkb_vascular_progression
    name: Genotype-stratified vascular inflammation and stenosis-progression study
    description: >-
      Combine longitudinal imaging of intracranial stenosis with molecular
      profiling of RNF213-genotyped MMD cohorts and matched vascular cells.
      Stratify patients by RNF213 p.R4810K status (homozygous, heterozygous,
      wild-type) and quantify IL6-Amp activation (NF-κB p65 and STAT3
      phosphorylation, IL-6 output) in superficial temporal artery samples and
      in patient-derived arachnoid/endothelial cells stimulated with TNF-α plus
      IL-6, while tracking radiographic stenosis progression over time. Test
      whether RNF213-TRAF2-dependent NF-κB signaling predicts and mechanistically
      precedes vascular remodeling.
    experiment_type:
      preferred_term: genotype-stratified translational cohort with cell-based mechanistic assays
    readouts:
    - name: Genotype-dependent IL6-Amp activation in vessel wall
      target: pathophysiology#RNF213-associated angiogenic and remodeling dysregulation
      description: >
        Quantify phosphorylated NF-κB p65 and STAT3 and IL-6 expression in
        superficial temporal artery tissue and stimulated patient-derived
        vascular cells across RNF213 genotypes to test whether the p.R4810K
        variant amplifies NF-κB/IL6-Amp inflammatory signaling.
      assays:
      - preferred_term: immunohistochemistry for phospho-NF-κB p65 and phospho-STAT3
      - preferred_term: IL-6 expression quantification in stimulated vascular cells
      direction: POSITIVE
    - name: NF-κB-dependence of inflammatory output
      target: pathophysiology#RNF213 loss-of-function Hippo-YAP/TAZ-VEGFR2 activation
      description: >
        Use RNF213 knockdown and TRAF2/NF-κB perturbation in vascular cell models
        to determine whether RNF213-driven IL-6 amplification is mediated through
        the TRAF2-NF-κB axis rather than the Hippo-YAP/TAZ-VEGFR2 program.
      assays:
      - preferred_term: RNF213 knockdown with NF-κB target-gene readout
      direction: POSITIVE
    - name: Inflammatory signature versus stenosis progression
      target: pathophysiology#Progressive steno-occlusive intracranial arteriopathy
      description: >
        Correlate baseline IL6-Amp/NF-κB activation markers with subsequent
        radiographic progression of intracranial stenosis to test whether
        inflammatory activation precedes and predicts steno-occlusive remodeling.
      assays:
      - preferred_term: serial neurovascular imaging of intracranial stenosis
      direction: POSITIVE
    decision_criterion: >-
      An RNF213-NF-κB/IL6-Amp inflammatory driver is supported if (1) p.R4810K
      genotype dose-dependently increases NF-κB p65/STAT3 phosphorylation and
      IL-6 output in vessel wall and patient-derived cells, (2) RNF213 knockdown
      suppresses inflammatory output in a TRAF2-NF-κB-dependent manner, and (3)
      baseline inflammatory activation predicts subsequent stenosis progression;
      a primarily parallel/amplifying role is favored if inflammatory markers
      do not precede or predict remodeling.
    would_support:
    - pathophysiology#RNF213-associated angiogenic and remodeling dysregulation
    - pathophysiology#Progressive steno-occlusive intracranial arteriopathy
  evidence:
  - reference: PMID:41891799
    reference_title: "RNF213-TRAF2 interaction enhances inflammatory responses via NF-κB activation in moyamoya disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here, we identify RNF213 as a critical regulator of the IL-6 amplifier (IL6-Amp), a mechanism that enhances NF-κB-mediated inflammation in the presence of IL-6-STAT3 in non-immune cells.
    explanation: >-
      This cell-based study identifies RNF213 as a regulator of the NF-κB-driven
      IL-6 amplifier, motivating the gap about whether this inflammatory axis is
      a central MMD mechanism.
  - reference: PMID:41891799
    reference_title: "RNF213-TRAF2 interaction enhances inflammatory responses via NF-κB activation in moyamoya disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The MMD-associated RNF213 p.R4810K variant enhanced NF-κB activation by strengthening the interaction between RNF213 and TRAF2, a key adaptor in TNF-α-NF-κB signaling.
    explanation: >-
      This biochemical/cell-based finding links the disease-associated p.R4810K
      variant to enhanced TRAF2-NF-κB
      signaling, supporting the gap question of how RNF213 genetic variation
      drives the inflammatory cascade.
- discussion_id: gap_moyamoya_rnf213_traf2_triggers_outcomes
  prompt: >-
    What are the precise upstream triggers that induce RNF213-TRAF2-mediated
    NF-κB activation and IL-6 amplification in cerebral vessels, and what are the
    downstream consequences of this inflammatory cascade for the characteristic
    progressive intracranial arterial stenosis and moyamoya collateral vessel
    formation that define moyamoya disease?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#RNF213-TRAF2-mediated NF-κB-IL-6 amplification
  - pathophysiology#Progressive steno-occlusive intracranial arteriopathy
  rationale: >-
    Inflammatory and autoimmune responses are implicated in moyamoya disease
    (MMD), but the precise molecular mechanisms remain poorly understood. RNF213
    is the key MMD susceptibility gene and has been linked to inflammatory
    signaling, yet its role in NF-κB-driven inflammation was unclear. Yasuda et
    al. (PMID:41891799) establish that RNF213 acts as a critical regulator of
    the IL-6 amplifier (IL6-Amp) and directly interacts with TRAF2 to enhance
    inflammatory NF-κB signaling, with the p.R4810K variant strengthening the
    RNF213-TRAF2 interaction. What remains unresolved is the upstream side of
    this axis — which physiological or environmental stimuli (e.g.,
    infection-associated cytokine exposure, TNF-α, IL-6) initiate IL6-Amp
    induction in cerebral vessel walls — and the downstream side: whether and
    how sustained NF-κB/IL-6 amplification mechanistically produces the medial
    and intimal remodeling, smooth-muscle and endothelial changes, and fragile
    collateral angiogenesis that manifest as progressive steno-occlusive
    arteriopathy. It is also unclear how RNF213 genetic variation, particularly
    the dose of p.R4810K, quantitatively tunes the inflammatory cascade and
    couples genotype to the rate and pattern of stenosis and collateral
    development. Resolving these upstream triggers and downstream effectors is
    needed to determine whether anti-inflammatory or anti-IL-6 intervention
    could modify disease progression.
  notes: "Seeded from PMID:41891799 — RNF213-TRAF2 interaction enhances inflammatory responses via NF-kB activation in moyamoya disease. Complements the broader same-source discussion gap_moyamoya_rnf213_nfkb, narrowing it to the unresolved upstream triggers and downstream steno-occlusive/collateral outcomes."

📚

References & Deep Research

Deep Research

1

Falcon ▸

Visual evidence note

Edison Scientific Literature 39 citations 2026-05-04T18:43:42.646899

1. Disease Information

1.1 Concise overview

Moyamoya disease (MMD) is a chronic, progressive cerebrovascular arteriopathy characterized by stenosis/occlusion centered on the terminal intracranial internal carotid arteries (and proximal branches) with development of abnormal collateral networks that produce a classic “moyamoya” (“puff-of-smoke”) appearance on angiography and related imaging (kappel2024managementofmoyamoya pages 1-2, kappel2024managementofmoyamoya pages 2-3, uchiyama2024adultmoyamoyadisease pages 2-3, uchiyama2024adultmoyamoyadisease pages 3-4).

Direct abstract quote (management review, 2024): “Moyamoya disease (MMD) is characterized by idiopathic, progressive stenosis of the circle of Willis and the terminal portion of the internal carotid arteries with the development of prominent small collateral vessels and a characteristic moyamoya or puff-of-smoke radiographic appearance.” (Oct 2024, Journal of Neurosurgery; URL: https://doi.org/10.3171/2024.1.jns221977) (kappel2024managementofmoyamoya pages 1-2).

1.2 Key identifiers (OMIM, Orphanet, ICD, MeSH, MONDO)

In the retrieved evidence, only OMIM:252350 was explicitly observed; MONDO, Orphanet (ORPHA), ICD-10/ICD-11 codes, and MeSH unique IDs were not present in the accessible excerpts (artifact-00). (kappel2024managementofmoyamoya pages 1-2, santos2025managementofmoyamoyab pages 3-4).

1.3 Common synonyms and alternative names

Common alternate labels used in the retrieved literature include moyamoya vasculopathy, moyamoya arteriopathy, moyamoya syndrome (MMS) (syndromic/secondary forms), and quasi-moyamoya disease (calandrelli2026moyamoyavasculopathyand pages 1-2, kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2).

1.4 Evidence source type

The information in this report is derived primarily from aggregated disease-level resources (peer-reviewed reviews, meta-analyses, and primary research studies), rather than individual EHR-derived patient summaries (artifact-00). (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2).

Field	Value	Notes/Evidence
Disease name	Moyamoya disease	Canonical name used throughout recent reviews; abbreviated MMD (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
Abbreviation	MMD	Explicitly defined as “Moyamoya disease (MMD)” (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
Related condition name	Moyamoya syndrome	Distinct term for moyamoya-like vasculopathy associated with other diseases/conditions; abbreviated MMS (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
Abbreviation	MMS	Explicitly defined as “moyamoya syndrome (MMS)” (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
Umbrella term / broader label	Moyamoya vasculopathy	Used as an umbrella term (MMV) in review literature (calandrelli2026moyamoyavasculopathyand pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
Abbreviation	MMV	Explicitly defined as “Moyamoya vasculopathy (MMV)” (calandrelli2026moyamoyavasculopathyand pages 1-2)
Synonym / related descriptor	Moyamoya arteriopathy	Used in recent management review as a related descriptor (kappel2024managementofmoyamoya pages 1-2)
Synonym / related descriptor	Quasi-moyamoya disease	Reported as a synonym/related label for syndromic or associated forms in review literature (kappel2024managementofmoyamoya pages 1-2)
Synonym / related descriptor	Moyamoya-like vasculopathy	Used to describe associated/systemic-disease forms (uchiyama2024adultmoyamoyadisease pages 1-2)
Synonym / related descriptor	Moyamoya-like patterns	Used for atypical radiologic patterns within the moyamoya spectrum (calandrelli2026moyamoyavasculopathyand pages 1-2)
Descriptive imaging phrase	Puff-of-smoke appearance	Characteristic collateral appearance repeatedly cited as descriptive terminology rather than a formal synonym (calandrelli2026moyamoyavasculopathyand pages 1-2, kappel2024managementofmoyamoya pages 1-2)
OMIM	252350	Retrieved evidence includes OMIM:252350 linked to moyamoya disease in older literature snippets (uchiyama2024adultmoyamoyadisease media e5baf62b)
MONDO ID	Not found in retrieved sources	No explicit MONDO identifier present in the provided evidence excerpts (calandrelli2026moyamoyavasculopathyand pages 1-2, kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
Orphanet / ORPHA ID	Not found in retrieved sources	No explicit Orphanet identifier present in the provided evidence excerpts (calandrelli2026moyamoyavasculopathyand pages 1-2, kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
ICD-10 code	Not found in retrieved sources	No explicit ICD-10 code present in the provided evidence excerpts (calandrelli2026moyamoyavasculopathyand pages 1-2, kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
ICD-11 code	Not found in retrieved sources	No explicit ICD-11 code present in the provided evidence excerpts (calandrelli2026moyamoyavasculopathyand pages 1-2, kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
MeSH descriptor	Moyamoya disease	MeSH-tagged disease term explicitly present in systematic-review indexing text, though no MeSH ID was provided in the evidence (santos2025managementofmoyamoyab pages 3-4, santos2025managementofmoyamoyaa pages 3-4)
MeSH ID	Not found in retrieved sources	Evidence shows MeSH term usage/subheadings but not the numeric/unique MeSH identifier (santos2025managementofmoyamoyab pages 3-4, santos2025managementofmoyamoyaa pages 3-4)
Evidence source level	Aggregated disease-level resources and reviews	Information summarized in retrieved evidence comes from reviews/guidelines and disease-level literature, not individual-patient EHR datasets (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)

Table: This table compiles the key names, abbreviations, and formal identifiers for Moyamoya disease that were explicitly available in the retrieved evidence. It is useful for normalizing terminology for a disease knowledge base while clearly flagging identifiers not found in the provided sources.

2. Etiology

2.1 Disease causal factors (genetic, environmental, mechanistic)

MMD is widely treated as a multifactorial disease with strong genetic susceptibility (most prominently RNF213 in East Asian populations) and additional environmental/inflammatory “second hits” contributing to penetrance and progression (kappel2024managementofmoyamoya pages 2-3, tan2024exploringrnf213in pages 4-6).

Key genetic susceptibility is emphasized in 2024–2025 reviews, including RNF213 and additional genes (e.g., ACTA2, DIAPH1, HLA, and rare Mendelian causes such as GUCY1A3 and BRCC3 in syndromic/familial contexts) (kappel2024managementofmoyamoya pages 1-2, he2025advancesinmoyamoya pages 8-10, he2025advancesinmoyamoya pages 13-14).

2.2 Risk factors

2.2.1 Genetic risk factors

RNF213 p.R4810K (c.14576G>A; founder in East Asia) is strongly enriched among East Asian MMD patients compared with the general population, with reported patient frequencies Japanese 90.1%, Korean 78.9%, Chinese 23.1% versus population carrier frequencies Japanese 2.5%, Korean 2.7%, Chinese 0.9% (Jul 2024 review; URL: https://doi.org/10.1159/000540254) (uchiyama2024adultmoyamoyadisease pages 2-3). A 2024 review further summarizes very large effect sizes in meta-analysis (ORs ~184 Japan, ~110 Korea, ~32 China) and also reports association with overall stroke risk in broader cohorts (OR 1.91, 95% CI 1.55–2.36) (Dec 2024 review; URL: https://doi.org/10.3390/biomedicines13010017) (tan2024exploringrnf213in pages 2-4).

Incomplete penetrance and zygosity effects: a 2024 RNF213-focused review reports low penetrance among heterozygotes (“1/150–1/300 of heterozygous carriers actually develop MMD”) with much higher incidence among homozygotes (“exceeding 78%”), emphasizing the need for additional modifiers and caution about population screening (tan2024exploringrnf213in pages 4-6).

2.2.2 Environmental/clinical risk factors and triggers

Radiation exposure is emphasized as a risk factor for moyamoya syndrome (secondary moyamoya arteriopathy) (kappel2024managementofmoyamoya pages 2-3).

Infectious/immune exposure as a progression modifier (gene–environment interaction): In a prospective cohort of 275 MMD patients, both RNF213 p.R4810K carrier status and a composite infectious-burden (IB) score were independently associated with more severe intracranial stenosis (Willis narrowing score). The RNF213 variant had OR 2.832 (95% CI 1.347–5.955; P=0.006) and IB had OR 1.771 (95% CI 1.286–2.439; P<0.001) for severe stenosis; high IB (≥5) corresponded to 50.0% severe stenosis vs 21.6% in low IB, adjusted aOR 3.212 (95% CI 1.861–5.542) (Mar 2025; URL: https://doi.org/10.1161/jaha.124.036830) (zeng2025rnf213variantand pages 5-8).

2.2.3 Protective factors

No explicit protective genetic variants or modifiable protective exposures were identified in the retrieved evidence excerpts; therefore, this section remains incompletely populated from available sources.

2.3 Gene–environment interactions

The 2025 prospective cohort provides direct evidence of gene–environment contributions to stenosis severity (RNF213 variant and infectious burden), and further shows interaction with modifiable metabolic factors: stronger IB effects in subgroups with higher BMI, triglycerides, and homocysteine (interaction P values reported <0.05 in the cohort report) (zeng2025rnf213variantand pages 1-2, zeng2025rnf213variantand pages 5-8).

3. Phenotypes

3.1 Core clinical phenotypes and patterns

Common clinical manifestations across the lifespan include transient ischemic attacks (TIAs), ischemic stroke, intracranial hemorrhage (more prominent in adults), seizures, headache, and cognitive impairment/cognitive decline (kappel2024managementofmoyamoya pages 1-2, kappel2024managementofmoyamoya pages 2-3, chakrabarti2025moyamoyadiseasephysiological pages 3-4).

Epidemiologic phenotype patterns reported in the 2024 management review include: - Pediatric series: 67.8% presenting with stroke and 2.8% hemorrhage (kappel2024managementofmoyamoya pages 1-2). - Adult Japanese cohort: 21% intracerebral hemorrhage (kappel2024managementofmoyamoya pages 1-2).

3.2 Age of onset and progression

MMD shows a bimodal age distribution, with pediatric diagnoses typically in ages ~5–9 years and adult presentation commonly in the 5th–6th decades (kappel2024managementofmoyamoya pages 2-3).

3.3 Quality of life impact

Recent reviews emphasize neurocognitive sequelae and cognitive deficits as important contributors to morbidity and quality-of-life impact, motivating ongoing registry studies centered on cognition and imaging biomarkers (NCT05619068 chunk 1, kappel2024managementofmoyamoya pages 1-2).

3.4 Suggested HPO terms

A structured phenotype-to-HPO mapping based on the retrieved evidence is provided below.

Clinical phenotype	Suggested HPO term(s)	Typical age group (pediatric/adult)	Notes on frequency/severity if available from evidence
Ischemic stroke / cerebral infarction	HP:0001297 Cerebral infarction; Ischemic stroke	Both; especially pediatric	Most common presentation overall; pediatric series cited in review reported 67.8% presenting with stroke, while children more often present with ischemia than hemorrhage (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 2-3)
Transient ischemic attack	HP:0002326 Transient ischemic attack	Both; common in pediatric and early disease	Frequently reported presenting manifestation; pediatric patients often present with stroke/TIA; RNF213-associated disease linked to earlier onset and TIAs in some summaries (kappel2024managementofmoyamoya pages 2-3, bagyinszky2025multisystemicimpactof pages 4-6)
Intracranial hemorrhage / hemorrhagic stroke	HP:0002170 Intracranial hemorrhage; Hemorrhagic stroke	More common in adults	Adult patients are nearly twice as likely as pediatric patients to present with intracranial hemorrhage; one adult Japanese cohort cited 21% intracerebral hemorrhage, versus only 2.8% hemorrhage in a pediatric series (kappel2024managementofmoyamoya pages 1-2, kappel2024managementofmoyamoya pages 2-3)
Seizures	HP:0001250 Seizure	Both; often pediatric but can occur in either	Recognized clinical manifestation; listed among common presentations in recent reviews, though no robust frequency estimate was provided in retrieved evidence (chakrabarti2025moyamoyadiseasephysiological pages 3-4, calandrelli2026moyamoyavasculopathyand pages 5-6)
Headache	HP:0002315 Headache	Both	Reported as a common presenting symptom in recent reviews; frequency not quantified in retrieved evidence (chakrabarti2025moyamoyadiseasephysiological pages 3-4)
Cognitive impairment / cognitive decline	HP:0100543 Cognitive impairment; Neurocognitive dysfunction	Both; may be more evident in chronic disease and adults	Reviews note cognitive deficits and neurocognitive sequelae affecting quality of life; homozygous RNF213 carriers may have greater cognitive impairment (chakrabarti2025moyamoyadiseasephysiological pages 3-4, bagyinszky2025multisystemicimpactof pages 4-6)
Developmental delay / neurodevelopmental impact	HP:0001263 Global developmental delay; Developmental delay	Pediatric	Pediatric chronic cerebral hypoperfusion can manifest with developmental delay; highlighted in review-level evidence rather than quantified cohort data (chakrabarti2025moyamoyadiseasephysiological pages 3-4)
Hemiparesis / focal neurologic deficit	HP:0001269 Hemiparesis; Focal neurologic deficit	Both	Common downstream manifestation of ischemic or hemorrhagic events; not separately quantified in retrieved evidence but clinically central to stroke presentation (kappel2024managementofmoyamoya pages 1-2, chakrabarti2025moyamoyadiseasephysiological pages 3-4)
Posterior cerebral artery involvement	HP term label: Posterior cerebral artery stenosis/occlusion	Both; associated with more severe disease	Important vascular phenotype and risk marker; associated with perioperative cerebral infarction risk (OR 2.62) and with RNF213-related severity in several reports (uchiyama2024adultmoyamoyadisease pages 3-4, bagyinszky2025multisystemicimpactof pages 4-6)
Progressive intracranial arterial stenosis / occlusion	HP term label: Intracranial arterial stenosis; Cerebral artery occlusion	Both	Core vascular phenotype of disease; terminal ICA-centered stenosis/occlusion with moyamoya collaterals is required for diagnosis. Severe stenosis is associated with RNF213 variant carriage and higher infectious burden (RNF213 OR 2.832; IB OR 1.771 for severe WNS) (uchiyama2024adultmoyamoyadisease pages 3-4, zeng2025rnf213variantand pages 5-8, zeng2025rnf213variantand pages 1-2)
Abnormal collateral vessel formation ("puff-of-smoke")	HP term label: Abnormal cerebral collateral circulation	Both	Hallmark angiographic phenotype; characteristic collateral network defines the disease radiographically, but this is an imaging phenotype rather than a patient-reported symptom (kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 2-3, uchiyama2024adultmoyamoyadisease pages 3-4)
Asymptomatic moyamoya arteriopathy	HP term label: Asymptomatic cerebrovascular disease	Both; increasingly detected in adults	Increasingly recognized through imaging; historical reports in review cite asymptomatic cases rising from 1.5% to 17.8%, with AMORE showing 1.0% annual stroke risk per hemisphere over 5 years (kappel2024managementofmoyamoya pages 1-2, kappel2024managementofmoyamoya pages 5-6)

Table: This table maps major clinical and vascular phenotypes of moyamoya disease to suggested HPO terms and summarizes age-pattern and severity/frequency notes drawn from the retrieved evidence. It is useful for structured phenotype annotation in a disease knowledge base.

4. Genetic/Molecular Information

4.1 Causal genes and susceptibility genes

RNF213 is the major susceptibility gene in East Asian MMD and is also discussed as a broader vasculopathy gene with diverse phenotypes (uchiyama2024adultmoyamoyadisease pages 2-3, tan2024exploringrnf213in pages 2-4).

Additional MMD-related genes are highlighted in 2024–2025 review literature (often as syndromic or secondary moyamoya causes/associations): GUCY1A3, BRCC3, and genes implicated in vascular smooth muscle and arterial disease spectra such as ACTA2, DIAPH1, and immune loci such as HLA (kappel2024managementofmoyamoya pages 1-2, he2025advancesinmoyamoya pages 8-10, he2025advancesinmoyamoya pages 13-14).

Gene (HGNC symbol)	Variant/example	Evidence type (human genetic association/functional model)	Key finding	Key quantitative statistic	Source (PMID/DOI/URL if in evidence)
RNF213	p.R4810K / c.14576G>A (also described as p.R4859K in one review)	Human genetic association	Major East Asian founder susceptibility variant for moyamoya disease; strongly enriched in familial and sporadic cases; associated with earlier onset and more severe disease	Japanese/Korean/Chinese MMD patient frequencies 90.1% / 78.9% / 23.1% vs general population 2.5% / 2.7% / 0.9%; OR ~144 for definite MMD and ~54 for unilateral MMD in cited cohorts (uchiyama2024adultmoyamoyadisease pages 2-3). Another review: Japan OR 184.04, Korea 109.77, China 31.53; stroke OR 1.91 (95% CI 1.55–2.36) (tan2024exploringrnf213in pages 2-4)	Uchiyama & Fujimura 2024, DOI: 10.1159/000540254, https://doi.org/10.1159/000540254 (uchiyama2024adultmoyamoyadisease pages 2-3); Tan et al. 2024, DOI: 10.3390/biomedicines13010017, https://doi.org/10.3390/biomedicines13010017 (tan2024exploringrnf213in pages 2-4)
RNF213	p.R4810K / c.14576G>A	Human genetic association; penetrance analysis	Strong effect but incomplete penetrance; zygosity influences severity and age at onset	General East Asian population frequency around 1–2%; only ~1/150–1/300 heterozygous carriers develop MMD, while homozygous disease incidence exceeds 78%; homozygotes median onset 3 years vs 7 years in heterozygotes (tan2024exploringrnf213in pages 4-6, tan2024exploringrnf213in pages 2-4)	Tan et al. 2024, DOI: 10.3390/biomedicines13010017, https://doi.org/10.3390/biomedicines13010017 (tan2024exploringrnf213in pages 2-4, tan2024exploringrnf213in pages 4-6)
RNF213	Loss-of-function; pathogenic mutations including CNV deletion and disease-associated missense variants	Functional model + human pathology	RNF213 loss promotes pathological angiogenesis and vascular remodeling; implicated in Hippo/YAP/TAZ→VEGFR2 dysregulation and intimal hyperplasia	In HBMECs, RNF213 knockdown increased endothelial proliferation/migration/tube formation; YAP/TAZ activation with p-TAZ/TAZ ~0.61 and p-YAP/YAP ~0.43; surface VEGFR2 ~1.28-fold and intracellular VEGFR2 ~0.59-fold vs control; severe WNS OR 2.832 for RNF213 variant in a prospective cohort (ye2023rnf213lossoffunctionpromotes pages 11-13, ye2023rnf213lossoffunctionpromotes pages 10-11, zeng2025rnf213variantand pages 5-8)	Ye et al. 2023, DOI: 10.1093/brain/awad225, https://doi.org/10.1093/brain/awad225 (ye2023rnf213lossoffunctionpromotes pages 11-13, ye2023rnf213lossoffunctionpromotes pages 10-11, ye2023rnf213lossoffunctionpromotes pages 1-2, ye2023rnf213lossoffunctionpromotes pages 2-3); Zeng et al. 2025, DOI: 10.1161/JAHA.124.036830, https://doi.org/10.1161/jaha.124.036830 (zeng2025rnf213variantand pages 5-8)
RNF213	Rare C-terminal / non-p.R4810K variants	Human genetic association	Allelic heterogeneity outside East Asia; rare C-terminal RNF213 variants reported in Caucasian moyamoya cases	Variant rare/absent in White/Caucasian cohorts in one review (maximum allele frequency reported 0.0006; absent in one WES series of 125 Caucasian patients) (he2025advancesinmoyamoya pages 8-10)	He et al. 2025, DOI: 10.1002/mco2.70054, https://doi.org/10.1002/mco2.70054 (he2025advancesinmoyamoya pages 8-10, bagyinszky2025multisystemicimpactof pages 17-18)
GUCY1A3	Loss-of-function mutations; compound heterozygous familial variants	Human genetic association	Supports nitric oxide/soluble guanylate cyclase pathway involvement; implicated in familial/syndromic moyamoya	Two compound heterozygotes among 96 sequenced cases in one report; larger case-control study (255 patients vs 300 controls) showed no association in another dataset (he2025advancesinmoyamoya pages 13-14)	He et al. 2025, DOI: 10.1002/mco2.70054, https://doi.org/10.1002/mco2.70054 (he2025advancesinmoyamoya pages 13-14)
BRCC3	Deletions / loss-of-function	Human genetic association	Causes X-linked syndromic moyamoya in case reports/families; supports abnormal angiogenesis pathway	Population studies referenced in a review showed no difference outside syndromic cases; quantitative association not established in broader cohorts in retrieved evidence (he2025advancesinmoyamoya pages 13-14)	He et al. 2025, DOI: 10.1002/mco2.70054, https://doi.org/10.1002/mco2.70054 (he2025advancesinmoyamoya pages 13-14)
ACTA2	Pathogenic mutations (specific variant not provided in retrieved evidence)	Review-level human genetic association	Implicated as a moyamoya-related gene beyond RNF213; especially relevant to syndromic/monogenic vasculopathy spectrum	No variant-specific quantitative statistic provided in retrieved evidence	He et al. 2025, DOI: 10.1002/mco2.70054, https://doi.org/10.1002/mco2.70054 (he2025advancesinmoyamoya pages 8-10); Kappel et al. 2024, DOI: 10.3171/2024.1.JNS221977, https://doi.org/10.3171/2024.1.jns221977 (kappel2024managementofmoyamoya pages 1-2)
DIAPH1	Pathogenic mutations (specific variant not provided in retrieved evidence)	Review-level human genetic association	Listed among MMD-related genes beyond RNF213 in recent review literature	No variant-specific quantitative statistic provided in retrieved evidence	He et al. 2025, DOI: 10.1002/mco2.70054, https://doi.org/10.1002/mco2.70054 (he2025advancesinmoyamoya pages 8-10)
HLA	HLA susceptibility loci/alleles (not specified in retrieved evidence)	Review-level human genetic association	HLA-region genetic susceptibility has been reported in MMD, supporting immune/inflammatory contribution	No variant-specific quantitative statistic provided in retrieved evidence	He et al. 2025, DOI: 10.1002/mco2.70054, https://doi.org/10.1002/mco2.70054 (he2025advancesinmoyamoya pages 8-10)

Table: This table summarizes the principal genes and representative variants implicated in moyamoya disease from the retrieved evidence, emphasizing RNF213 p.R4810K and other genes named in recent reviews. It is useful for quickly distinguishing strong human genetic associations from lower-detail review-level gene mentions and mechanistic model evidence.

4.2 Pathogenic variants (example variants and mechanistic consequences)

RNF213 loss-of-function mechanisms (primary 2023 functional study)

A key 2023 Brain paper provides multi-system mechanistic evidence that RNF213 loss-of-function promotes pathological angiogenesis via Hippo pathway dysregulation:

Direct abstract quote (Jul 2023, Brain): “RNF213 deletion exacerbated pathological angiogenesis… Reduced RNF213 expression led to increased endothelial cell proliferation, migration and tube formation… Endothelial knockdown of RNF213 activated the Hippo pathway effector Yes-associated protein (YAP)/tafazzin (TAZ) and promoted the overexpression of the downstream effector VEGFR2… inhibition of YAP/TAZ… reversed RNF213 knockdown-induced angiogenesis.” (URL: https://doi.org/10.1093/brain/awad225) (ye2023rnf213lossoffunctionpromotes pages 1-2).

Quantitative molecular readouts reported include altered Hippo phosphorylation ratios and VEGFR2 trafficking: p-TAZ/TAZ ~0.61 and p-YAP/YAP ~0.43 (lower than control), with increased surface VEGFR2 (~1.28-fold) and reduced intracellular VEGFR2 (~0.59-fold) in RNF213 knockdown endothelial cells (ye2023rnf213lossoffunctionpromotes pages 11-13).

RNF213 variant penetrance and severity

RNF213 p.R4810K shows incomplete penetrance in heterozygotes with very high incidence in homozygotes, consistent with a “susceptibility + second hit” model rather than a fully penetrant Mendelian cause in most populations (tan2024exploringrnf213in pages 4-6).

4.3 Modifier genes

The retrieved excerpts do not provide a validated list of modifier genes with quantified effect on severity; however, multiple reviews frame MMD as polygenic/multifactorial with additional genes (ACTA2/DIAPH1/HLA and others) that may influence phenotype heterogeneity (he2025advancesinmoyamoya pages 8-10).

4.4 Epigenetic information (2024 focus)

A 2024 Molecular Therapy – Nucleic Acids review summarizes multiple epigenetic layers implicated in MMD: - DNA methylation: promoter hypomethylation of SORT1 in endothelial colony-forming cells (ECFCs) from MMD patients, with increased SORT1 expression and downstream pro-angiogenic factor changes (VEGF/VEGFR-1/bFGF/MMP9 up; Ang-1 and thrombospondin 2 down) (xu2024insightsintothe pages 3-4). - Histone modifications: reduced acetyl-histone H3K27 binding at RALDH2 promoter with reduced RALDH2 expression (retinoic acid synthesis) in ECFCs; HDAC inhibitor panobinostat reportedly restored impaired angiogenic potential in that context (xu2024insightsintothe pages 3-4). - Noncoding RNAs: multiple circulating or CSF miRNA/circRNA signatures are discussed as candidate biomarkers and mechanistic drivers; examples include serum let-7c, CSF exosome miRNA panels, and multiple differentially expressed circRNAs (xu2024insightsintothe pages 16-17, xu2024insightsintothe pages 13-14).

5. Environmental Information

5.1 Environmental factors

The retrieved 2024 management review identifies CNS infections and radiation exposure (particularly for moyamoya syndrome) as notable non-genetic contributors, alongside circulating cytokines/growth factors and autoantibodies as signals of inflammatory contribution (kappel2024managementofmoyamoya pages 1-2).

5.2 Lifestyle/metabolic factors

The prospective gene–environment cohort indicates that infectious-burden associations with stenosis severity were amplified among patients with higher BMI, triglycerides, and homocysteine—suggesting potentially modifiable metabolic contexts may influence progression (zeng2025rnf213variantand pages 1-2).

5.3 Infectious agents

The infectious-burden score in the prospective cohort was built from antibody titers to HSV-1/2, CMV, Toxoplasma, rubella, and EBV, and was associated with more severe stenosis in MMD (zeng2025rnf213variantand pages 2-4, zeng2025rnf213variantand pages 5-8).

6. Mechanism / Pathophysiology

6.1 Causal chain (integrated current understanding)

A synthesis supported by the retrieved evidence is: 1) Genetic susceptibility (especially RNF213 p.R4810K in East Asia) establishes a predisposition with incomplete penetrance (uchiyama2024adultmoyamoyadisease pages 2-3, tan2024exploringrnf213in pages 4-6). 2) Second-hit exposures (e.g., inflammatory/infectious burden; radiation in syndromic cases) and metabolic context can contribute to progression/severity (zeng2025rnf213variantand pages 5-8, kappel2024managementofmoyamoya pages 2-3). 3) At the vessel wall level, disease is characterized by steno-occlusive remodeling and collateral network formation; RNF213 perturbation can drive endothelial dysfunction and aberrant angiogenesis (kappel2024managementofmoyamoya pages 1-2, ye2023rnf213lossoffunctionpromotes pages 1-2). 4) A demonstrated molecular axis in endothelial models is Hippo pathway “off” signaling → YAP/TAZ activation → VEGFR2 dysregulation/trafficking changes → hyperangiogenic phenotype, observed in human brain microvascular endothelial cells and corroborated in mouse and zebrafish models (ye2023rnf213lossoffunctionpromotes pages 10-11, ye2023rnf213lossoffunctionpromotes pages 11-13, ye2023rnf213lossoffunctionpromotes pages 1-2).

6.2 Molecular pathways (examples supported by retrieved evidence)

Hippo pathway / YAP–TAZ–TEAD and VEGF/VEGFR2 signaling dysregulation in RNF213 loss-of-function endothelial models (ye2023rnf213lossoffunctionpromotes pages 10-11, ye2023rnf213lossoffunctionpromotes pages 1-2).
Inflammatory signaling and barrier integrity: management review summarizes associations with cytokines/growth factors, autoantibodies, and blood–brain barrier junctional protein alterations as part of the mechanistic landscape (kappel2024managementofmoyamoya pages 2-3).

6.3 Immune system involvement

Immune/inflammatory contributions are supported by (i) review-level discussions of cytokines/autoantibodies/infections and (ii) the prospective infectious-burden severity association (kappel2024managementofmoyamoya pages 1-2, zeng2025rnf213variantand pages 5-8).

6.4 Suggested ontology terms

GO biological process (suggestions): angiogenesis; regulation of endothelial cell proliferation; regulation of endothelial cell migration; VEGF receptor signaling pathway; Hippo signaling; regulation of vascular remodeling; inflammatory response; blood–brain barrier maintenance (ye2023rnf213lossoffunctionpromotes pages 1-2, kappel2024managementofmoyamoya pages 2-3).

CL cell types (suggestions): brain microvascular endothelial cell; vascular smooth muscle cell; endothelial colony-forming cell (ECFC) (ye2023rnf213lossoffunctionpromotes pages 1-2, xu2024insightsintothe pages 3-4).

7. Anatomical Structures Affected

7.1 Organ and vascular territories

Primary involvement is intracranial arterial circulation centered on the terminal intracranial internal carotid artery and proximal MCA/ACA involvement; collateral networks form near the lesions (uchiyama2024adultmoyamoyadisease pages 3-4).

7.2 Lateralization

Updated diagnostic criteria allow unilateral disease; unilateral cases can progress to bilateral disease (uchiyama2024adultmoyamoyadisease pages 1-2, uchiyama2024adultmoyamoyadisease pages 3-4).

7.3 Suggested UBERON terms (suggestions)

Intracranial internal carotid artery; middle cerebral artery; anterior cerebral artery; circle of Willis; basal ganglia; periventricular white matter.

8. Temporal Development

8.1 Onset

Bimodal onset/diagnosis: pediatric (~5–9 years) and adult (5th–6th decades) (kappel2024managementofmoyamoya pages 2-3).

8.2 Progression

MMD is described as progressive steno-occlusive arteriopathy. In asymptomatic cases, a disease registry analysis cited in the management review reports an annual stroke risk of 1.0% per moyamoya hemisphere over the first 5 years, with a predominance of hemorrhagic strokes among events (85.7%) (kappel2024managementofmoyamoya pages 2-3, kappel2024managementofmoyamoya pages 5-6).

9. Inheritance and Population

9.1 Epidemiology (statistics)

The 2024 management review provides region-specific incidence and prevalence trends: - Japan incidence reported 0.35/100,000 (1994) to 0.54/100,000 (2003) (kappel2024managementofmoyamoya pages 2-3). - Korea incidence increased 1.7→2.3/100,000 (2007–2011) and prevalence increased 8.2→16.1/100,000 by 2011 (kappel2024managementofmoyamoya pages 2-3). - Taiwan incidence increased 0.14→0.20/100,000 person-years (2000–2011) (kappel2024managementofmoyamoya pages 2-3). - Denmark incidence ~0.07/100,000 person-years (2008–2017) and U.S. ~0.086/100,000 person-years (kappel2024managementofmoyamoya pages 2-3).

Sex ratio: approximately 1.8–2.2 female-to-male ratio is reported (kappel2024managementofmoyamoya pages 1-2, kappel2024managementofmoyamoya pages 2-3).

Familial aggregation: family history reported in ~10–15% (kappel2024managementofmoyamoya pages 2-3).

9.2 Inheritance and penetrance

RNF213 p.R4810K is best described (in these sources) as a strong susceptibility allele with autosomal-dominant pattern and incomplete penetrance; penetrance is very low for heterozygotes but much higher for homozygotes (tan2024exploringrnf213in pages 4-6, tan2024exploringrnf213in pages 2-4).

10. Diagnostics

10.1 Clinical criteria and imaging

The 2021 Revised Diagnostic Criteria for MMD (Japanese RCMD guidance, summarized in 2024 review literature) include: - Diagnosis can be made in unilateral or bilateral cases. - Required radiologic features include stenosis/occlusion centered on the terminal intracranial ICA and the presence of moyamoya vessels (abnormal vascular networks) near the occlusive lesions. - Heavy T2-weighted MRI demonstration of decreased outer diameter of terminal ICA/horizontal MCA is emphasized to distinguish MMD from atherosclerosis; 3D-CISS MRI is highlighted as useful for this differentiation (uchiyama2024adultmoyamoyadisease pages 3-4, uchiyama2024adultmoyamoyadisease pages 1-2).

A visual table from the 2024 review shows the Suzuki angiographic staging system (I–VI) and indicates where the diagnostic criteria table is located in the paper (uchiyama2024adultmoyamoyadisease media e5baf62b, uchiyama2024adultmoyamoyadisease media aace831c).

10.2 Scoring systems

Quantitative MRA scoring (Houkin MRA score) correlating with Suzuki staging is used to grade arterial involvement (uchiyama2024adultmoyamoyadisease pages 2-3, uchiyama2024adultmoyamoyadisease pages 3-4).

10.3 Differential diagnosis

MMD must be distinguished from mimics such as intracranial atherosclerosis; imaging emphasis on outer arterial diameter reduction on heavy T2/3D-CISS supports this differentiation (uchiyama2024adultmoyamoyadisease pages 3-4).

11. Outcome / Prognosis

11.1 Natural history and stroke risk

Asymptomatic MMD is increasingly detected on imaging; a registry analysis cited in the 2024 management review reported 1.0% annual stroke risk per hemisphere over 5 years, with 85.7% hemorrhagic among observed strokes (kappel2024managementofmoyamoya pages 1-2, kappel2024managementofmoyamoya pages 5-6).

11.2 Post-surgical functional outcomes (pediatric meta-analysis)

In pediatric revascularization meta-analysis (37 studies; 2,460 patients; 4,432 hemispheres), functional outcomes at last follow-up (mRS 0–1) were pooled at ~80.38% for indirect bypass and ~87.44% for direct/combined bypass; mortality was very low (pooled indirect bypass mortality 0.30%) (Feb 2023; URL: https://doi.org/10.1007/s00381-023-05868-6) (lee2023surgicalrevascularizationsfor pages 12-13).

12. Treatment

12.1 Current standard of care and real-world implementation

Surgical revascularization is the mainstay for symptomatic MMD, including direct, indirect, and combined extracranial-intracranial bypass techniques; indirect approaches rely on angiogenic potential and are described as more effective in children, while direct/combined bypasses are described as more effective in adults (kappel2024managementofmoyamoya pages 5-6).

Adjunctive antiplatelet therapy (e.g., aspirin in pediatric practice in the U.S.) is used for ischemic symptom prevention, though the retrieved evidence excerpts did not provide pooled randomized effect estimates (kappel2024managementofmoyamoya pages 5-6).

12.2 Comparative effectiveness and safety (pediatric)

Pediatric meta-analysis found no significant differences between direct/combined versus indirect bypass for stroke recurrence, morbidity, or mortality, but direct/combined had better angiographic revascularization (Matsushima Grade A/B RR 1.12, 95% CI 1.02–1.24) and higher wound complication risk (RR 2.54, 95% CI 1.82–3.55) (lee2023surgicalrevascularizationsfor pages 1-2).

12.3 Postoperative monitoring and complications

A 2025 systematic review/meta-analysis supports noninvasive ultrasonography for postoperative bypass assessment with predictive changes in STA/ECA flow parameters (e.g., STA PSV MD 28.26 within 2 weeks for high bypass capacity) (santos2025managementofmoyamoyaa pages 1-3).

12.4 MAXO suggestions

A structured treatment-to-MAXO mapping (labels suggested) is provided below.

Treatment/strategy	MAXO term suggestion (label)	Indication (e.g., symptomatic ischemic, hemorrhagic, pediatric)	Evidence summary	Key quantitative outcome if available	Sources
Direct extracranial-intracranial bypass (e.g., STA-MCA bypass)	surgical revascularization procedure; extracranial-intracranial arterial bypass	Symptomatic adult MMD, especially ischemic; also used in hemorrhagic disease	Review evidence indicates surgical revascularization is the mainstay for symptomatic disease; direct and combined bypass appear more effective than indirect bypass in adults for prevention of recurrent stroke/hemorrhage. Endovascular stenting has generally not prevented progression, reinforcing surgery as standard definitive therapy.	Adult comparative metrics not quantified in retrieved full evidence excerpts; qualitative consensus favors direct/combined over indirect in adults.	(kappel2024managementofmoyamoya pages 5-6, uchiyama2024adultmoyamoyadisease pages 1-2)
Indirect bypass (e.g., EDAS/EMS/encephaloduroarteriosynangiosis-based approaches)	indirect cerebral revascularization procedure	Pediatric MMD/MMS; symptomatic ischemic disease; patients with small recipient vessels	Indirect procedures rely on angiogenic potential and are described as particularly effective in children. Pediatric meta-analysis found indirect bypass to be overall safe and effective, though angiographic collateralization was somewhat better with direct/combined strategies.	In pediatric meta-analysis, no significant difference vs direct/combined for stroke recurrence, morbidity, or mortality; wound complications were lower than direct/combined.	(kappel2024managementofmoyamoya pages 5-6, lee2023surgicalrevascularizationsfor pages 1-2, lee2023surgicalrevascularizationsfor pages 12-13)
Combined direct + indirect bypass	combined surgical revascularization procedure	Adult symptomatic MMD; selected pediatric cases; situations seeking immediate + delayed collateral supply	Reviews report combined/direct bypasses perform better in adults than indirect alone. Pediatric meta-analysis suggests improved long-term angiographic revascularization versus indirect bypass, but without clear long-term stroke or mortality advantage.	Matsushima Grade A/B angiographic revascularization favored direct/combined over indirect: RR 1.12 (95% CI 1.02-1.24); wound complications higher with direct/combined: RR 2.54 (95% CI 1.82-3.55).	(kappel2024managementofmoyamoya pages 5-6, lee2023surgicalrevascularizationsfor pages 1-2, lee2023surgicalrevascularizationsfor pages 12-13)
Antiplatelet therapy (aspirin; clopidogrel; short dual antiplatelet therapy in some adults)	antiplatelet therapy	Adjunctive therapy for ischemic presentations; peri-diagnostic/medical management; pediatric aspirin commonly used in U.S. practice	Antiplatelet therapy is used as adjunctive medical management, especially for ischemic symptoms. Review notes aspirin is commonly used in children and some adult studies suggest fewer ischemic events with aspirin, clopidogrel, or short dual therapy, but this is adjunctive rather than disease-modifying.	No pooled effect size provided in retrieved evidence excerpts.	(kappel2024managementofmoyamoya pages 5-6, uchiyama2024adultmoyamoyadisease pages 1-2)
Conservative management with serial imaging surveillance	clinical surveillance; watchful waiting	Asymptomatic MMD; some stable MMS/MMV cases; patients without clear hemodynamic compromise	Asymptomatic disease is generally managed conservatively with watchful waiting and serial imaging. For moyamoya syndrome/vasculopathy, conservative management plus treatment of the underlying disorder is emphasized unless progressive symptoms or chronic hemodynamic insufficiency develop.	AMORE study cited in review: annual stroke risk 1.0% per moyamoya hemisphere over 5 years; 85.7% of strokes were hemorrhagic.	(kappel2024managementofmoyamoya pages 5-6, kappel2024managementofmoyamoya pages 2-3, calandrelli2026moyamoyavasculopathyand pages 5-6, kappel2024managementofmoyamoya pages 1-2)
Secondary prevention directed at underlying syndrome/comorbidity	secondary prevention strategy; treatment of underlying disease	Moyamoya syndrome / quasi-moyamoya associated with radiation, autoimmune disease, sickle cell disease, NF1, etc.	MMS is defined by moyamoya-pattern arteriopathy with comorbid conditions. Management is pattern-specific and often conservative, emphasizing treatment of the associated condition and surveillance; revascularization is considered for progressive neurologic symptoms/hemodynamic insufficiency.	No quantitative comparative outcome in retrieved excerpts.	(uchiyama2024adultmoyamoyadisease pages 2-3, calandrelli2026moyamoyavasculopathyand pages 5-6, kappel2024managementofmoyamoya pages 1-2, uchiyama2024adultmoyamoyadisease pages 1-2)
Postoperative ultrasonographic bypass assessment	postoperative imaging assessment; ultrasonography monitoring	After revascularization surgery to assess bypass function/capacity	Ultrasound is a noninvasive postoperative monitoring tool for bypass capacity when compared with confirmatory imaging. It is useful for identifying high bypass capacity after surgery.	Meta-analysis of 8 cohort studies/301 hemispheres: early high-capacity bypass associated with increased STA PSV (MD 28.26, p<0.0001), MFV (MD 22.97, p=0.03), EDV (MD 33.45, p<0.0001), and lower RI (MD -0.09, p=0.006).	(santos2025managementofmoyamoyaa pages 1-3)
Risk-stratified perioperative management	perioperative management	Surgical candidates with prior infarction, PCA involvement, advanced MRA severity	Meta-analysis identified factors associated with perioperative cerebral infarction, supporting enhanced perioperative monitoring and risk stratification rather than a distinct therapy.	Posterior cerebral artery involvement OR 2.62 (95% CI 1.36-5.06); higher preoperative MRA grade OR 2.81 (95% CI 1.27-6.22); previous infarction OR 2.52 (95% CI 1.69-3.75).	(santos2025managementofmoyamoyaa pages 1-3)
Growth-factor/angiogenesis adjuncts (VEGF, HGF, PDGF; investigational)	pro-angiogenic therapy	Experimental adjunct to improve collateral formation after bypass	Current reviews describe no approved disease-modifying therapy; proposed future approaches include growth-factor augmentation to improve neovascularization and bypass vessel ingrowth.	No clinical efficacy data in retrieved evidence excerpts.	(kappel2024managementofmoyamoya pages 5-6)
Gene-targeted therapy / CRISPR-style approaches (investigational)	gene therapy	Future personalized therapy for familial/genetically susceptible MMD	Reviews highlight RNF213 and other susceptibility genes as rationale for future genome-informed therapies, but these remain conceptual/experimental and not established clinical care.	No human outcome data in retrieved evidence excerpts.	(kappel2024managementofmoyamoya pages 5-6, ye2023rnf213lossoffunctionpromotes pages 11-13, ye2023rnf213lossoffunctionpromotes pages 1-2)

Table: This table summarizes current and emerging management strategies for moyamoya disease, aligned to suggested MAXO-style action labels. It is useful for mapping evidence-based interventions, indications, and quantitative outcomes into a structured disease knowledge base.

12.5 Experimental and clinical-trial landscape (real-world ongoing research)

Recent/ongoing ClinicalTrials.gov records in the retrieved evidence include: - NCT04205578 (Phase 3 RCT): dl-3-n-butylphthalide (NBP) perioperative adjunct after EC–IC bypass; planned enrollment 450; primary endpoints include perioperative ischemic stroke and death within 30 days (registered 2020) (NCT04205578 chunk 1). - NCT04917003 (randomized controlled interventional; phase NA): remote ischemic conditioning (RIC) + EDAS vs EDAS in ischemic MMD; enrollment 60; primary outcome change in relative CBF in operative MCA territory at 3 months (registered 2021) (NCT04917003 chunk 1). - NCT02319980 (Phase 3 randomized): combined revascularization (STA–MCA + EDMS) vs conservative management in adult hemorrhagic MMD; enrollment 360; primary includes strokes/death within 30 days and ipsilateral recurrent bleeding up to 5 years (registered 2015) (NCT02319980 chunk 1). - NCT02982135 (non-randomized interventional): direct vs indirect bypass in adult hemorrhagic MMD; enrollment 300; primary outcome rebleeding events over 5–10 years (registered 2016) (NCT02982135 chunk 1). - NCT05619068 (prospective observational registry): evolution/prognosis with imaging biomarkers and cognitive decline; enrollment 300; compares conservative vs revascularization pathways (registered 2022) (NCT05619068 chunk 1).

13. Prevention

13.1 Primary prevention

No validated primary prevention strategy is established in the retrieved evidence excerpts; genetic susceptibility has incomplete penetrance and likely requires additional triggers (tan2024exploringrnf213in pages 4-6).

13.2 Secondary and tertiary prevention

Secondary prevention focuses on stroke prevention and surveillance, including conservative management with serial imaging for asymptomatic cases and surgical revascularization for symptomatic or hemodynamically compromised disease, with adjunctive antiplatelet therapy commonly used for ischemic presentations (kappel2024managementofmoyamoya pages 5-6).

14. Other Species / Natural Disease

No naturally occurring disease in non-human species was identified in the retrieved evidence excerpts.

15. Model Organisms

15.1 Model types and what they show

A high-impact 2023 study used RNF213-deficient mice and zebrafish to demonstrate increased/pathological angiogenesis, and used human brain microvascular endothelial cell (HBMEC) knockdown to demonstrate increased proliferation/migration/tube formation linked to Hippo/YAP/TAZ→VEGFR2 signaling (ye2023rnf213lossoffunctionpromotes pages 1-2, ye2023rnf213lossoffunctionpromotes pages 11-13).

These models support a mechanistic link from genetic perturbation (RNF213 loss-of-function) to endothelial behavior changes and abnormal vascular network development consistent with moyamoya-like collateral formation, while recognizing that reproducing the full steno-occlusive large-artery phenotype in models remains challenging (ye2023rnf213lossoffunctionpromotes pages 1-2).

Visual evidence note

Tables summarizing the Suzuki angiographic staging system and the 2021 RCMD diagnostic/imaging criteria are present as extracted images from the 2024 review (uchiyama2024adultmoyamoyadisease media e5baf62b, uchiyama2024adultmoyamoyadisease media aace831c).

Evidence and coverage limitations

Formal ontology codes (MONDO, ORPHA, ICD-10/11, MeSH unique ID) were not present in the accessible retrieved excerpts, so they cannot be asserted from this evidence alone (artifact-00).
Several requested areas (protective factors; specific validated prognostic biomarkers; robust adult comparative surgical outcome statistics) were only partially supported by the retrieved evidence set.

References

(kappel2024managementofmoyamoya pages 1-2): Ari D Kappel, Abdullah H. Feroze, Erickson F. Torio, Madhav Sukumaran, and Rose Du. Management of moyamoya disease: a review of current and future therapeutic strategies. Journal of Neurosurgery, 141:975-982, Oct 2024. URL: https://doi.org/10.3171/2024.1.jns221977, doi:10.3171/2024.1.jns221977. This article has 27 citations and is from a domain leading peer-reviewed journal.
(kappel2024managementofmoyamoya pages 2-3): Ari D Kappel, Abdullah H. Feroze, Erickson F. Torio, Madhav Sukumaran, and Rose Du. Management of moyamoya disease: a review of current and future therapeutic strategies. Journal of Neurosurgery, 141:975-982, Oct 2024. URL: https://doi.org/10.3171/2024.1.jns221977, doi:10.3171/2024.1.jns221977. This article has 27 citations and is from a domain leading peer-reviewed journal.
(uchiyama2024adultmoyamoyadisease pages 2-3): S. Uchiyama and Miki Fujimura. Adult moyamoya disease and moyamoya syndrome: what is new? Cerebrovascular Diseases Extra, 14:86-94, Jul 2024. URL: https://doi.org/10.1159/000540254, doi:10.1159/000540254. This article has 15 citations and is from a peer-reviewed journal.
(uchiyama2024adultmoyamoyadisease pages 3-4): S. Uchiyama and Miki Fujimura. Adult moyamoya disease and moyamoya syndrome: what is new? Cerebrovascular Diseases Extra, 14:86-94, Jul 2024. URL: https://doi.org/10.1159/000540254, doi:10.1159/000540254. This article has 15 citations and is from a peer-reviewed journal.
(santos2025managementofmoyamoyab pages 3-4): DE Santos, G Chmutin, and E Chmutin. Management of moyamoya disease: a systematic review and meta-analysis on surgical revascularization, outcomes and clinical manifestations. Unknown journal, 2025.
(calandrelli2026moyamoyavasculopathyand pages 1-2): Rosalinda Calandrelli, Carlo Augusto Mallio, Caterina Bernetti, Luca Massimi, and Fabio Pilato. Moyamoya vasculopathy and atypical moyamoya-like patterns: insights into diagnosis and therapeutic implications. NeuroSci, 7:27, Feb 2026. URL: https://doi.org/10.3390/neurosci7010027, doi:10.3390/neurosci7010027. This article has 0 citations.
(uchiyama2024adultmoyamoyadisease pages 1-2): S. Uchiyama and Miki Fujimura. Adult moyamoya disease and moyamoya syndrome: what is new? Cerebrovascular Diseases Extra, 14:86-94, Jul 2024. URL: https://doi.org/10.1159/000540254, doi:10.1159/000540254. This article has 15 citations and is from a peer-reviewed journal.
(uchiyama2024adultmoyamoyadisease media e5baf62b): S. Uchiyama and Miki Fujimura. Adult moyamoya disease and moyamoya syndrome: what is new? Cerebrovascular Diseases Extra, 14:86-94, Jul 2024. URL: https://doi.org/10.1159/000540254, doi:10.1159/000540254. This article has 15 citations and is from a peer-reviewed journal.
(santos2025managementofmoyamoyaa pages 3-4): DE Santos, G Chmutin, and E Chmutin. Management of moyamoya disease: a systematic review and meta-analysis on surgical revascularization, outcomes and clinical manifestations. Unknown journal, 2025.
(tan2024exploringrnf213in pages 4-6): Benjamin Y. Q. Tan, Charlene H. P. Kok, Megan B. J. Ng, Shaun Loong, Eric Jou, Leonard L. L. Yeo, Weiping Han, Christopher D. Anderson, Chiea Chuen Khor, and Poh San Lai. Exploring rnf213 in ischemic stroke and moyamoya disease: from cellular models to clinical insights. Biomedicines, 13:17, Dec 2024. URL: https://doi.org/10.3390/biomedicines13010017, doi:10.3390/biomedicines13010017. This article has 10 citations.
(he2025advancesinmoyamoya pages 8-10): Shihao He, Zhenyu Zhou, Michelle Y. Cheng, Xiaokuan Hao, Terrance Chiang, Yanru Wang, Junze Zhang, Xilong Wang, Xun Ye, Rong Wang, Gary K. Steinberg, and Yuanli Zhao. Advances in moyamoya disease: pathogenesis, diagnosis, and therapeutic interventions. MedComm, Jan 2025. URL: https://doi.org/10.1002/mco2.70054, doi:10.1002/mco2.70054. This article has 31 citations.
(he2025advancesinmoyamoya pages 13-14): Shihao He, Zhenyu Zhou, Michelle Y. Cheng, Xiaokuan Hao, Terrance Chiang, Yanru Wang, Junze Zhang, Xilong Wang, Xun Ye, Rong Wang, Gary K. Steinberg, and Yuanli Zhao. Advances in moyamoya disease: pathogenesis, diagnosis, and therapeutic interventions. MedComm, Jan 2025. URL: https://doi.org/10.1002/mco2.70054, doi:10.1002/mco2.70054. This article has 31 citations.
(tan2024exploringrnf213in pages 2-4): Benjamin Y. Q. Tan, Charlene H. P. Kok, Megan B. J. Ng, Shaun Loong, Eric Jou, Leonard L. L. Yeo, Weiping Han, Christopher D. Anderson, Chiea Chuen Khor, and Poh San Lai. Exploring rnf213 in ischemic stroke and moyamoya disease: from cellular models to clinical insights. Biomedicines, 13:17, Dec 2024. URL: https://doi.org/10.3390/biomedicines13010017, doi:10.3390/biomedicines13010017. This article has 10 citations.
(zeng2025rnf213variantand pages 5-8): Chaofan Zeng, Peicong Ge, Zihan Yin, Junlin Lu, Xiaofan Yu, Junsheng Li, Yuanren Zhai, Chenglong Liu, Qiheng He, Wei Liu, Jia Wang, Xingju Liu, Xun Ye, Qian Zhang, Rong Wang, Yan Zhang, Dong Zhang, and Jizong Zhao. rnf213 variant and infectious burden associated with intracranial artery stenosis in moyamoya disease. Journal of the American Heart Association, Mar 2025. URL: https://doi.org/10.1161/jaha.124.036830, doi:10.1161/jaha.124.036830. This article has 2 citations.
(zeng2025rnf213variantand pages 1-2): Chaofan Zeng, Peicong Ge, Zihan Yin, Junlin Lu, Xiaofan Yu, Junsheng Li, Yuanren Zhai, Chenglong Liu, Qiheng He, Wei Liu, Jia Wang, Xingju Liu, Xun Ye, Qian Zhang, Rong Wang, Yan Zhang, Dong Zhang, and Jizong Zhao. rnf213 variant and infectious burden associated with intracranial artery stenosis in moyamoya disease. Journal of the American Heart Association, Mar 2025. URL: https://doi.org/10.1161/jaha.124.036830, doi:10.1161/jaha.124.036830. This article has 2 citations.
(chakrabarti2025moyamoyadiseasephysiological pages 3-4): Kaustov Chakrabarti. Moyamoya disease: physiological mechanisms and treatment approaches. Apr 2025. URL: https://doi.org/10.20944/preprints202504.1113.v1, doi:10.20944/preprints202504.1113.v1.
(NCT05619068 chunk 1): Xin Lou. The Evolution and Prognosis of Moyamoya Disease. Chinese PLA General Hospital. 2022. ClinicalTrials.gov Identifier: NCT05619068
(bagyinszky2025multisystemicimpactof pages 4-6): Eva Bagyinszky, YoungSoon Yang, and Seong Soo A. An. Multisystemic impact of rnf213 arg4810lys: a comprehensive review of moyamoya disease and associated vasculopathies. International Journal of Molecular Sciences, 26:7864, Aug 2025. URL: https://doi.org/10.3390/ijms26167864, doi:10.3390/ijms26167864. This article has 5 citations.
(calandrelli2026moyamoyavasculopathyand pages 5-6): Rosalinda Calandrelli, Carlo Augusto Mallio, Caterina Bernetti, Luca Massimi, and Fabio Pilato. Moyamoya vasculopathy and atypical moyamoya-like patterns: insights into diagnosis and therapeutic implications. NeuroSci, 7:27, Feb 2026. URL: https://doi.org/10.3390/neurosci7010027, doi:10.3390/neurosci7010027. This article has 0 citations.
(kappel2024managementofmoyamoya pages 5-6): Ari D Kappel, Abdullah H. Feroze, Erickson F. Torio, Madhav Sukumaran, and Rose Du. Management of moyamoya disease: a review of current and future therapeutic strategies. Journal of Neurosurgery, 141:975-982, Oct 2024. URL: https://doi.org/10.3171/2024.1.jns221977, doi:10.3171/2024.1.jns221977. This article has 27 citations and is from a domain leading peer-reviewed journal.
(ye2023rnf213lossoffunctionpromotes pages 11-13): Fei Ye, Xingyang Niu, Feng Liang, Yuanyuan Dai, Jie Liang, Jiaoxing Li, Xiaoxin Wu, Hanyue Zheng, Tiewei Qi, and Wenli Sheng. Rnf213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the hippo pathway. Brain, 146:4674-4689, Jul 2023. URL: https://doi.org/10.1093/brain/awad225, doi:10.1093/brain/awad225. This article has 60 citations and is from a highest quality peer-reviewed journal.
(ye2023rnf213lossoffunctionpromotes pages 10-11): Fei Ye, Xingyang Niu, Feng Liang, Yuanyuan Dai, Jie Liang, Jiaoxing Li, Xiaoxin Wu, Hanyue Zheng, Tiewei Qi, and Wenli Sheng. Rnf213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the hippo pathway. Brain, 146:4674-4689, Jul 2023. URL: https://doi.org/10.1093/brain/awad225, doi:10.1093/brain/awad225. This article has 60 citations and is from a highest quality peer-reviewed journal.
(ye2023rnf213lossoffunctionpromotes pages 1-2): Fei Ye, Xingyang Niu, Feng Liang, Yuanyuan Dai, Jie Liang, Jiaoxing Li, Xiaoxin Wu, Hanyue Zheng, Tiewei Qi, and Wenli Sheng. Rnf213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the hippo pathway. Brain, 146:4674-4689, Jul 2023. URL: https://doi.org/10.1093/brain/awad225, doi:10.1093/brain/awad225. This article has 60 citations and is from a highest quality peer-reviewed journal.
(ye2023rnf213lossoffunctionpromotes pages 2-3): Fei Ye, Xingyang Niu, Feng Liang, Yuanyuan Dai, Jie Liang, Jiaoxing Li, Xiaoxin Wu, Hanyue Zheng, Tiewei Qi, and Wenli Sheng. Rnf213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the hippo pathway. Brain, 146:4674-4689, Jul 2023. URL: https://doi.org/10.1093/brain/awad225, doi:10.1093/brain/awad225. This article has 60 citations and is from a highest quality peer-reviewed journal.
(bagyinszky2025multisystemicimpactof pages 17-18): Eva Bagyinszky, YoungSoon Yang, and Seong Soo A. An. Multisystemic impact of rnf213 arg4810lys: a comprehensive review of moyamoya disease and associated vasculopathies. International Journal of Molecular Sciences, 26:7864, Aug 2025. URL: https://doi.org/10.3390/ijms26167864, doi:10.3390/ijms26167864. This article has 5 citations.
(xu2024insightsintothe pages 3-4): Shuangxiang Xu, Tong-Tong Chen, Jin Yu, Lei Wan, Jianjian Zhang, Jincao Chen, Wei Wei, and Xiang Li. Insights into the regulatory role of epigenetics in moyamoya disease: current advances and future prospectives. Molecular Therapy - Nucleic Acids, 35:102281, Sep 2024. URL: https://doi.org/10.1016/j.omtn.2024.102281, doi:10.1016/j.omtn.2024.102281. This article has 12 citations.
(xu2024insightsintothe pages 16-17): Shuangxiang Xu, Tong-Tong Chen, Jin Yu, Lei Wan, Jianjian Zhang, Jincao Chen, Wei Wei, and Xiang Li. Insights into the regulatory role of epigenetics in moyamoya disease: current advances and future prospectives. Molecular Therapy - Nucleic Acids, 35:102281, Sep 2024. URL: https://doi.org/10.1016/j.omtn.2024.102281, doi:10.1016/j.omtn.2024.102281. This article has 12 citations.
(xu2024insightsintothe pages 13-14): Shuangxiang Xu, Tong-Tong Chen, Jin Yu, Lei Wan, Jianjian Zhang, Jincao Chen, Wei Wei, and Xiang Li. Insights into the regulatory role of epigenetics in moyamoya disease: current advances and future prospectives. Molecular Therapy - Nucleic Acids, 35:102281, Sep 2024. URL: https://doi.org/10.1016/j.omtn.2024.102281, doi:10.1016/j.omtn.2024.102281. This article has 12 citations.
(zeng2025rnf213variantand pages 2-4): Chaofan Zeng, Peicong Ge, Zihan Yin, Junlin Lu, Xiaofan Yu, Junsheng Li, Yuanren Zhai, Chenglong Liu, Qiheng He, Wei Liu, Jia Wang, Xingju Liu, Xun Ye, Qian Zhang, Rong Wang, Yan Zhang, Dong Zhang, and Jizong Zhao. rnf213 variant and infectious burden associated with intracranial artery stenosis in moyamoya disease. Journal of the American Heart Association, Mar 2025. URL: https://doi.org/10.1161/jaha.124.036830, doi:10.1161/jaha.124.036830. This article has 2 citations.
(uchiyama2024adultmoyamoyadisease media aace831c): S. Uchiyama and Miki Fujimura. Adult moyamoya disease and moyamoya syndrome: what is new? Cerebrovascular Diseases Extra, 14:86-94, Jul 2024. URL: https://doi.org/10.1159/000540254, doi:10.1159/000540254. This article has 15 citations and is from a peer-reviewed journal.
(lee2023surgicalrevascularizationsfor pages 12-13): Keng Siang Lee, John J. Y. Zhang, Sanjay Bhate, Vijeya Ganesan, Dominic Thompson, Greg James, and Adikarige Haritha Dulanka Silva. Surgical revascularizations for pediatric moyamoya: a systematic review, meta-analysis, and meta-regression analysis. Child's Nervous System, 39:1225-1243, Feb 2023. URL: https://doi.org/10.1007/s00381-023-05868-6, doi:10.1007/s00381-023-05868-6. This article has 23 citations.
(lee2023surgicalrevascularizationsfor pages 1-2): Keng Siang Lee, John J. Y. Zhang, Sanjay Bhate, Vijeya Ganesan, Dominic Thompson, Greg James, and Adikarige Haritha Dulanka Silva. Surgical revascularizations for pediatric moyamoya: a systematic review, meta-analysis, and meta-regression analysis. Child's Nervous System, 39:1225-1243, Feb 2023. URL: https://doi.org/10.1007/s00381-023-05868-6, doi:10.1007/s00381-023-05868-6. This article has 23 citations.
(santos2025managementofmoyamoyaa pages 1-3): DE Santos, G Chmutin, and E Chmutin. Management of moyamoya disease: a systematic review and meta-analysis on surgical revascularization, outcomes and clinical manifestations. Unknown journal, 2025.
(NCT04205578 chunk 1): yuanli Zhao. NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events. yuanli Zhao. 2020. ClinicalTrials.gov Identifier: NCT04205578
(NCT04917003 chunk 1): Ji Xunming,MD,PhD. Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya Disease. Capital Medical University. 2021. ClinicalTrials.gov Identifier: NCT04917003
(NCT02319980 chunk 1): Hanqiang Jiang,MD. The Adult Hemorrhagic Moyamoya Surgery Study. Huashan Hospital. 2015. ClinicalTrials.gov Identifier: NCT02319980
(NCT02982135 chunk 1): liuxingju. Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease. liuxingju. 2016. ClinicalTrials.gov Identifier: NCT02982135

Ask OpenScientist

OpenScientist Report

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

Deep Research

1. Disease Information

1.1 Concise overview

1.2 Key identifiers (OMIM, Orphanet, ICD, MeSH, MONDO)

1.3 Common synonyms and alternative names

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors (genetic, environmental, mechanistic)

2.2 Risk factors

2.2.1 Genetic risk factors

2.2.2 Environmental/clinical risk factors and triggers

2.2.3 Protective factors

2.3 Gene–environment interactions

3. Phenotypes

3.1 Core clinical phenotypes and patterns

3.2 Age of onset and progression

3.3 Quality of life impact

3.4 Suggested HPO terms

4. Genetic/Molecular Information

4.1 Causal genes and susceptibility genes

4.2 Pathogenic variants (example variants and mechanistic consequences)

RNF213 loss-of-function mechanisms (primary 2023 functional study)

RNF213 variant penetrance and severity

4.3 Modifier genes

4.4 Epigenetic information (2024 focus)

5. Environmental Information

5.1 Environmental factors

5.2 Lifestyle/metabolic factors

5.3 Infectious agents

6. Mechanism / Pathophysiology

6.1 Causal chain (integrated current understanding)

6.2 Molecular pathways (examples supported by retrieved evidence)

6.3 Immune system involvement

6.4 Suggested ontology terms

7. Anatomical Structures Affected

7.1 Organ and vascular territories

7.2 Lateralization

7.3 Suggested UBERON terms (suggestions)

8. Temporal Development

8.1 Onset

8.2 Progression

9. Inheritance and Population

9.1 Epidemiology (statistics)

9.2 Inheritance and penetrance

10. Diagnostics

10.1 Clinical criteria and imaging

10.2 Scoring systems

10.3 Differential diagnosis

11. Outcome / Prognosis

11.1 Natural history and stroke risk

11.2 Post-surgical functional outcomes (pediatric meta-analysis)

12. Treatment

12.1 Current standard of care and real-world implementation

12.2 Comparative effectiveness and safety (pediatric)

12.3 Postoperative monitoring and complications

12.4 MAXO suggestions

12.5 Experimental and clinical-trial landscape (real-world ongoing research)

13. Prevention

13.1 Primary prevention

13.2 Secondary and tertiary prevention

14. Other Species / Natural Disease

15. Model Organisms

15.1 Model types and what they show

Visual evidence note

Evidence and coverage limitations